



ECIO 2019

European Conference
on Interventional Oncology

April 8-11, 2019

Amsterdam, Netherlands



**LEADERS IN ONCOLOGIC
INTERVENTIONS**

POCKET GUIDE

www.ecio.org



Cardiovascular and Interventional Radiological Society of Europe

The ECIO 2019 event in the CIRSE society app

Your toolkit for ECIO 2019 in Amsterdam:

- browse the programme
- build your personal schedule
- complete the session evaluation
- participate in e-voting polls
- send questions to the moderators
- find your way around using the interactive floor plan
- browse the list of exhibitors
- watch sessions live and on demand
- and much more...
























Available for iOS and Android



Monday, April 8


Tuesday, April 9

Wednesday, April 10

30																
45																
08:00																
15																
30																
45																
09:00	 MA CF 101 HCC – what you should know p19			 MA CF 801 Intrahepatic cholangiocarcinoma p25			Aud.II CF 802 Immunotherapy: actual clinical applications – what an IR should know p26			 MA CF 1501 Kidney cancer – current controversies p33			Aud.II CF 1502 Immunotherapy: where are we heading (research) p33		SS SED-HO 4 Safe sedation application during IR procedures p16	
10:00	Break			Break						Break						
11:00	 MA CF 201 Cancer immunology: basics p20	 Aud.II TF 202 Image guidance: case-based discussion p20	Aud.III TA-HDT 1 Tumour ablation – RFA p14	 MA HL 901 Honorary Lecture p26	Aud.III TA-HDT 3 Tumour ablation – Microwave p14	SS SED-HO 1 Safe sedation application during IR procedures p16	 MA CF 1601 Cancer pain management p34	  Aud.II CF 1602 Emergency in oncology p35	Aud.III TA-HDT 5 Tumour ablation – Cryo- and laser p14	SS SED-HO 5 Safe sedation application during IR procedures p16						
12:00	Lunch break			Lunch break						Lunch break						
13:00	SY 301 Satellite Symposium p63			SY 1001 Satellite Symposium p67			SS SED-HO 2 Safe sedation application during IR procedures p16	SY 1701 Satellite Symposium p73			MA SED-HO 6 Safe sedation application during IR procedures p16					
14:00	SY 302 Satellite Symposium p65			SY 1002 Satellite Symposium p69			SY 1702 Satellite Symposium p73									
15:00	Break			Break						Break						
16:00	 MA CF 401 Hepato-carcinoma – practice in 2019 p21	Aud.II CF 402 Other organs p22	Aud.III TA-HDT 2 Tumour ablation – RFA p14	 Aud.II CF 1101 Lung metastases p29	 MA CF 1102 Colorectal liver metastases p30	Aud.III TA-HDT 4 Tumour ablation – Microwave p14	SS SED-HO 3 Safe sedation application during IR procedures p16	 MA MTB 1801 MSK p36	Aud.II VL 1802 How I do it p37	Aud.III TA-HDT 6 Tumour ablation – Image guidance p14						
17:00	Break			Break						Break						
18:00	 MA CF 501 Colorectal p23	 Aud.II TF 502 Tips and tricks: case-based discussion p24	 Aud.III BC 503 Basic Course: Liver p24	 MA CF 1201 SBRT of liver and lung tumours: understanding mechanisms and limitations p31	 Aud.II CF 1202 MSK: curative treatment p31	 Aud.III BC 1203 Basic Course: Liver p32	 MA CF 1901 Response assessment and follow-up imaging p38	Aud.II FP 1902 Free Paper Session 2 p39	 Aud.III BC 1903 Basic Course: Liver p41							
19:00	SY 601 Satellite Symposium p65			SY 1301 Satellite Symposium p71												
30																

Wednesday, April 11

			30
			45
			08:00
			15
			30
			45
			09:00
			15
			30
			45
			10:00
			15
			30
			45
			11:00
			15
			30
			45
			12:00

	Aud.II	MA
CF 2101		
New indications: localised prostate cancer		
	p42	p42
CF 2102		
Quality issues, research and patterns of practice in interventional oncology		
Break		
		MA
MM 2201		
Morbidity & Mortality Conference		
		p43

CF: Clinical Focus Session
TF: Technical Focus Session
MTB: Multidisciplinary Tumour Board
VL: Video Learning Session
HL: Honorary Lecture
HDT: Hands-on Device Training
SED: Safe Sedation Training
BC: Basic Course
FP: Free Paper Session
MM: Morbidity and Mortality

MA: Main Auditorium
Aud. II: Auditorium II
Aud. III: Auditorium III (G 103)
MR. I: Meeting Room I (G 110)
SS: Safe Sedation (G 107)



e-voting




Sessions include lectures that are recommended for EBIR preparation

© Cardiovascular and Interventional Radiological Society of Europe / 2019. CIRSE does not accept responsibility for errors or misprints.

LEADERS IN ONCOLOGIC INTERVENTIONS

ECIO 2019

LIVE AND ON DEMAND



live.ecio.org

Can't make it to the congress?

You can watch all sessions in HD quality via our live stream!

Can't decide which session to go to?

Pick one and watch the other lectures on demand in the CIRSE Library!

Interested in more interventional content?

The CIRSE Library is the largest online presentation database for interventional radiology, featuring slides and webcasts from past CIRSE meetings. CIRSE members have year-round free access to all live congresses and webcast recordings. Find out more about our various access options for non-members at cirse.org/library/access.

4	4 Important Addresses, 5 Committees, 6 General Information, 12 Honorary Lecture, 14 Hands-on Device Training, 16 Safe Sedation Training	
19	Monday – Scientific Programme	MON
25	Tuesday – Scientific Programme	TUE
33	Wednesday – Scientific Programme	WED
42	Thursday – Scientific Programme	THU
45	Posters	POSTERS
61	Corporate Activities 63 Satellite Symposia 75 Learning Centres 79 Hands-on Training Sponsors	
80	Exhibitors and Sponsors 80 Sponsors 82 Technical Exhibition, Alphabetical List 83 Technical Exhibition, Numerical List 84 Technical Exhibitors Guide	

Important Addresses

Congress Venue

RAI Convention Centre

Europaplein 2-22
1078 GZ Amsterdam
Netherlands

Organising Secretariat

CIRSE Central Office

Neutorgasse 9
1010 Vienna
Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

Email: info@cirse.org

www.ecio.org

The European Conference on Interventional Oncology is organised by CIRSE (Cardiovascular and Interventional Radiological Society of Europe).

The official congress website is: www.ecio.org

To contact the CIRSE Central Office or members of the committee, please write to info@cirse.org.

Committees

Scientific Programme Committee

Afshin Gangi (FR), Chairperson

Alban Denys (CH), Deputy Chairperson

David J. Breen (UK)

Laura Crocetti (IT)

Thierry de Baère (FR)

Fabrizio Fanelli (IT)

Thomas K. Helmberger (DE)

Riccardo Lencioni (US)

Gabriel Malouf (FR)

Robert A. Morgan (UK)

Jean Palussière (FR)

Philippe L. Pereira (DE)

Warner Prevoo (NL)

Tarun Sabharwal (UK)

José Urbano (ES)

Otto M. van Delden (NL)

Local Host Committee

Otto M. van Delden (Amsterdam), Chairperson

Marc Besselink (Amsterdam)

Rutger Bruijnen (Arnhem)

Marc Burgmans (Leiden)

Jurgen J. Fütterer (Nijmegen)

Hein-Josef Klümpen (Amsterdam)

Mirjam Koopman (Utrecht)

Martijn Meijerink (Amsterdam)

Adriaan Moelker (Rotterdam)

Warner Prevoo (Amsterdam)

Christian van der Leij (Maastricht)

Cees Verhoef (Rotterdam)

General Information from A to Z

App

Let the CIRSE app take care of your congress planning. Newcomers, please download the CIRSE society app which is available for iPhone, iPad and Android and install the ECIO 2019 event. If the CIRSE society app is already on your smartphone, just install the ECIO 2019 event and have the best toolkit to:



- build your personal schedule
- complete the session evaluation
- search for exhibitors by product category
- take part in voting
- submit questions to the moderators in select sessions

Badges

Your personalised badge is your admission card to the congress. For organisational and security reasons, badges must be worn at the congress venue at all times. A lanyard will be given to you with the congress bag. Identity checks in the congress centre may occur at any time. In case the badge is lost, a replacement badge will be provided for an administrative charge of €80.

Certificate of Attendance

To obtain your certificate of attendance, you can choose one of the following options:

Print your certificate onsite at the congress

From 10:00 on Wednesday, April 10, you can use one of the dedicated workstations in the registration area to print your certificate. All you need is your congress badge.

Print your certificate at home

After the congress you will be able to print your certificate of attendance at www.ecio.org. All you will need is your last name and badge number. Alternatively, you could log into your personal CIRSE account at www.cirse.org with your personal log-in details.

CME Credit Allowance

ECIO 2019 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 21 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Coffee Breaks, Snacks & Meals

During the breaks refreshments can be purchased at the café bars located either side of the Exhibition hall.

A complimentary lunch buffet provided by our Diamond sponsors will be available in the exhibition area. Lunch will be from 12:00-13:00, with an additional complimentary coffee and refreshments break from 14:30-15:00.

Disclaimer

CIRSE cannot accept any liability for the acts of the meeting suppliers or the attendees' safety while travelling to or from the congress. All participants are strongly advised to carry adequate travel and health insurance, as CIRSE cannot accept liability for accidents or injuries that may occur.

Disclosures

For financial disclosures and conflict-of-interest statements, please refer to www.ecio.org.

Evaluation

To complete the session evaluation and obtain credits for your attendance at ECIO 2019 sessions, please use the online evaluation system, accessible through the CIRSE mobile app (please see page 6) and at <http://programme.ecio.org/>



Internet

Free wireless service is available to all delegates throughout the congress centre.

Network: ECIO2019

Password: ecio2019

Live and On Demand – live.ecio.org

All sessions are being livestreamed and will be available directly on demand in the CIRSE Library. Never miss another session! CIRSE members have year-round free access to all live congresses and webcast recordings. Find out more about our various access options for non-members at cirse.org/library/access.

The CIRSE Library is the largest online presentation database for interventional radiology, featuring slides and webcasts from past CIRSE meetings. With monthly compiled topic packages, the CIRSE Library is the ideal tool for your research and educational needs. Presentations recorded at ECIO 2019 will be available immediately.

Mobile Phones

Please do not forget to turn your mobile phone to silent mode during the sessions.

Photographs and Video Recording

Please note that any form of recording, filming or photographing of presentation material during the sessions is strictly forbidden. Subject to the authors' consent, all presentation material will be made available online in the CIRSE Library – library.cirse.org.

Poster Area

All accepted scientific and educational posters will be presented electronically through ECIO's Electronic Poster Online System. For a detailed list of all posters, please refer to pages 45-60. The Poster Area is located on the first floor (please see the floorplan on the inside back cover).

Opening Hours

Monday, April 8	07:30-18:30
Tuesday, April 9	07:30-18:30
Wednesday, April 10	07:30-18:30
Thursday, April 11	07:30-18:30

Publication in CVIR

Meeting abstracts are published in CIRSE's official journal, CVIR, as an electronic supplementary issue, and are therefore citable publications.

Online Publication Number: 10.1007/s00270-019-02165-1

We encourage submission of the complete manuscript of oral or poster presentations for consideration to CVIR. Please submit your manuscript through the CVIR submission website on www.editorialmanager.com/cvir. Please note that all submissions have to comply with the "CVIR Instructions for Authors" specified on the CVIR submission website.

Registration Desk – Opening Hours

Sunday, April 7	16:00-18:00
Monday, April 8	07:30-18:00
Tuesday, April 9	08:00-18:00
Wednesday, April 10	08:00-18:00
Thursday, April 11	08:00-12:00

Smoking

The ECIO Annual Meeting is a non-smoking congress. Smoking is only permitted outside the congress centre.

Speaker Centre

The Speaker Centre is located on the first floor. All material must be in English and provided on a CD-ROM, DVD-ROM or USB flash drive (which is preferred) to be placed on the central server onsite. All presentation files must be uploaded at least three hours prior to the beginning of the corresponding session.

Computers connected to the local server allowing access to the speakers' presentations are available in every lecture room. These computers are equipped with Microsoft Windows 10 Professional and Microsoft Office 2016 Professional. Please note that speakers are not allowed to use their own laptops for their presentations.

Opening Hours

Sunday, April 7	16:00-18:00
Monday, April 8	07:45-18:00
Tuesday, April 9	07:45-18:00
Wednesday, April 10	08:00-18:00
Thursday, April 11	08:00-12:00

Technical Exhibition

Please find a floor plan of the exhibition on the inside of the back cover and a detailed list of all exhibitors and sponsors on pages 80-120.

Opening Hours

Monday, April 8	09:30-17:30
Tuesday, April 9	09:30-17:30
Wednesday, April 10	09:30-17:30
Thursday, April 11	09:30-12:30

Tourist Information and Hospitality Desk

For information regarding restaurants and excursions, please refer to the desk of our official travel partner Kuoni Congress located at registration. Our colleagues from Kuoni Congress will be pleased to help you with all matters related to your stay in Amsterdam.

CIRSE academy

**Your online learning platform
for interventional oncology
and beyond.**

All courses are curated by
leading global experts and tailored
to **EBIR exam preparation**.

You can obtain **CME points**
by completing the **1–2 hour courses**:

- **Colorectal liver metastases**
- **Hepatocellular carcinoma**
- **Lung metastases**
- **Metastatic bone disease**
- **Primary lung cancer**
- **Renal cancer**

CME
accredited

Anytime, anywhere –
your foundations
of interventional oncology

cirse.org/education/academy

Leaders in Oncologic Interventions

Ricardo García-Mónaco

Honorary Lecturer



Ricardo García-Mónaco completed his medical degree with honours at the University of Buenos Aires in 1981, before successfully sitting the boards of Radiology and Imaging Diagnosis of Argentina's National Ministry of Health in 1988. A fluent speaker of Spanish, English and French, he acquired a Diplome de Résonance Magnétique from the University of Paris in 1990, before returning to Argentina and taking up a double post as Associate Professor of Radiology and Programme Director of Interventional and Vascular Radiology at the University of Buenos Aires in 1996.

Prof. García-Mónaco completed his Doctorate (PhD) in medicine in 2004, and became a full Professor of Radiology at the University of Buenos Aires in 2007, the same year he became Director of the university's radiology medical school programme, a position he still holds.

His extensive post-graduate training took him to many corners of the earth: following his initial residencies at the Hospital Italiano in Buenos Aires, he completed training in Angiography and Interventional Radiology at Bicêtre Hospital, University of Paris from 1988-1992, and Visiting Fellowships at both New York University, USA and Toronto Western Hospital, Canada in 1990.

Returning then to France, he worked as Médecin Assistant a Titre Etranger at Hôpital Bicêtre and as a Consultant IR at the renowned Institut Gustav Roussy in Villejuif. Since 1992, Prof. García-Mónaco has been Head of Endovascular Therapy and Interventional Radiology at Hospital Italiano, and since 2005, also holds the post of Chairman of the hospital's Department of Radiology.

His international medical career is complemented by his active membership of many medical associations, including the Radiological Society of Argentina (SAR), the World Federation of Therapeutic and Interventional Neuroradiology, CIRSE, RSNA, the Société Française de Radiologie (SFR), ESR, the International Society for the Study of Vascular Anomalies (ISSVA), the Society

of Hepato-Gastroenterology and the International Society for Strategic Studies in Radiology (ISSSR). He is an SIR Fellow, and is also a Founding Member of the Argentine College of Vascular and Interventional Radiology (CARVI), which he currently serves as President. Prof. García-Mónaco is also the current president of the International Society of Radiology, and has previously served as President of Sociedad Argentina de Radiología and the Interamerican College of Radiology.

Prof. García-Mónaco is a prolific researcher and educator, having delivered 477 scientific or educational presentations at national or international congresses, and having 227 scientific papers published in national or international journals. He is also author or co-author of over 70 books or book chapters. He is a peer-reviewer for acclaimed journals such as *CVIR*, *Radiology*, *JVIR*, *Thrombosis* and *Radiographics*, and serves on the Editorial Committees of *Interventional Oncology 360*, *Digestive Disease Interventions* and *Revista de la Sociedad Iberoamericana de Intervencionismo*, amongst others.

Prof. García-Mónaco has received awards for 39 scientific presentations (24 national and 15 international), and has been conferred honorary membership of ESR, RSNA, the Société Française de Radiologie and the Societa Italiana de Radiologia Medica (SIRM), amongst others. He has received the Gold Medal of the Argentine Society of Radiology (SAR), and has served on many advisory boards and educational committees, including his current posts as a Member of the ISSSR Membership Committee, Member of RSNA Vascular/Interventional Education Exhibits Subcommittee and Chairman of the IT Education Committee of ISR.

Honorary Lecture

Interventional Oncology: from Europe to South America

Tuesday, April 9, 10:30-11:30, Main Auditorium

Hands-on Device Training

Tumour ablation

Percutaneous ablation plays an increasingly fundamental role in the loco-regional treatment of cancer. Ablation technologies and equipment for live image guidance are developing quickly.

This Hands-on Device Training (HDT) aims to provide an overview of available technologies. Separate sessions will look at radiofrequency ablation, microwave ablation, cryoablation and laser ablation, as well as image guidance.

After a short kick-off presentation by the HDT coordinators, participants will have the opportunity to learn about the specifics, as well as the safe and effective use of the available technology in a hands-on setting.

Each HDT will feature a round-table discussion with the coordinators at the end of each session allowing participants to ask questions and give feedback.

Monday, April 8**TA-HDT 1 – Radiofrequency** 10:30-12:00**TA-HDT 2 – Radiofrequency** 15:00-16:30*Coordinators: J.M. Abadal (Madrid/ES), F. Orsi (Milan/IT)***Tuesday, April 9****TA-HDT 3 – Microwave** 10:30-12:00**TA-HDT 4 – Microwave** 15:00-16:30*Coordinators: S. Ilyas (London/UK), P. Rao (Strasbourg/FR)***Wednesday, April 10****TA-HDT 5 – Cryoablation
and laser ablation** 10:30-12:00*Coordinators:**F.M. Gómez (Barcelona/ES), A.H. Mahnken (Marburg/DE)***TA-HDT 6 – Image guidance** 15:00-16:30*Coordinators:**A. Hakimé (Villejuif/FR), L. Solbiati (Rozzano/IT)***Location****Auditorium III (G 103)**

Please note that participation is free of charge, but places are limited to 25 people per session and will be allocated on a first come, first served basis.

As HDT sessions offer practical medical training, participation is for qualified medical professionals only.

For an overview of the industry partners supporting the Hands-on Device Training sessions, please refer to page 79.

Hands-on Training

Safe sedation application during IR procedures

This practical workshop will give participants the opportunity to perform procedural sedation in a simulated environment and inform them on the most common respiratory problems during procedural sedation, as well as which instruments are available to make these interventions safer.

The simulation set-up consists of a full-scale patient simulator with capnography, BIS monitoring and TIVA/TCI pumps. Participants will perform these therapies under the supervision of AQAI's experienced trainers.

Learning objectives:

- To apply procedural sedation using different approaches.
- To identify complications and challenges during procedural sedation.
- To judge on the value of various monitoring technologies.
- To recognise the additional value of capnography during sedation.

Tuesday, April 9

SED-HO 1	10:30-12:00
SED-HO 2	13:00-14:30
SED-HO 3	15:00-16:30

Wednesday, April 10

SED-HO 4	08:30-10:00
SED-HO 5	10:30-12:00
SED-HO 6	13:00-14:30

Coordinators:

M. Heinrichs (Mainz/DE), W. Heinrichs (Mainz/DE)

Location

Safe Sedation (G 107)

Please note that participation is free of charge, but places are limited to 25 people per session and will be allocated on a first come, first served basis.

As HDT sessions offer practical medical training, participation is for qualified medical professionals only.

For an overview of the industry partners supporting the Hands-on Training sessions, please refer to page 79.



European Board of
Interventional Radiology

Apply Now

and boost your career in IR

This globally recognised certification is designed to give practising IRs the opportunity to certify their expertise and build their career from early on.

Upcoming examinations:

- February – ECR 2020
- September – CIRSE 2020

Take part and submit
your application online at
www.cirse.org/ebir



Cardiovascular and Interventional Radiological Society of Europe

Monday, April 8

08:30-10:00, Main Auditorium

Clinical Focus Session

CF 101 HCC – what you should know

*Moderators: H.-J. Klümpen (Amsterdam/NL),
M. Ronot (Clichy/FR)*



101.1 HCC guidelines – what is new?

M. Varela (Oviedo/ES)



101.2 Percutaneous ablation: best indication and which energy

A. Hocquelet (Lausanne/CH)



101.3 Radioembolisation: who is a good candidate after the new classification

J. Ricke (Munich/DE)

101.4 Lessons learned from “Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study”

M. Ronot (Clichy/FR)

101.5 Intermediate stage: what are the indications for combined IO therapies?

R. Lencioni (Pisa/IT)



101.6 HCC and immunotherapy

H.-J. Klümpen (Amsterdam/NL)



e-voting



recommended for EBIR preparation

10:30-12:00, Main Auditorium

Clinical Focus Session

CF 201 Cancer immunology: basics

*Moderators: G.J. Adema (Nijmegen/NL),
M. Ahmed (Boston, MA/US)*

- 201.1 Immune alterations in solid tumours
W.H. Fridman (Paris/FR)
- 201.2 Immune checkpoint inhibitors – how do they work?
A. Digkila (Lausanne/CH)
- 201.3 Immune response: the role of the tumour
G. Malouf (Strasbourg/FR)
- 201.4 Immune response: the role of the microenvironment
C. Ottensmeier (Southampton/UK)
- 201.5 Mechanisms of priming immune response using local treatment
M. Ahmed (Boston, MA/US)

10:30-12:00, Auditorium II



Clinical Focus Session

TF 202 Image guidance: case-based discussion

*Moderators: P. Haage (Wuppertal/DE),
P.L. Pereira (Heilbronn/DE)*

- 202.1 Ultrasound fusion guidance
L. Solbiati (Rozzano/IT)
- 202.2 I have a CBCT and I do all the procedures
M.J.L. van Strijen (Nieuwegein/NL)
- 202.3 I have an angio plus CT and I do all the procedures
F.G. Irani (Singapore/SG)
- 202.4 MR-guided interventions: where are we?
R.L. Cazzato (Strasbourg/FR)
- 202.5 Robotic and stereotaxic assistance in IO
B.J. Wood (Bethesda, MD/US)
- 202.6 Augmented reality
A. Gangi (Strasbourg/FR)

10:30-12:00, Auditorium III (G 103)

Hands-on Device Training

TA-HDT 1 Tumour ablation – Radiofrequency

*Coordinators: J.M. Abadal (Madrid/ES),
F. Orsi (Milan/IT)*

13:00-13:45, Main Auditorium

SY 301 Satellite Symposium

For the programme, please refer to page 63.

13:45-14:30, Main Auditorium

SY 302 Satellite Symposium

For the programme, please refer to page 65.

15:00-16:30, Main Auditorium

Clinical Focus Session

CF 401 Hepatocarcinoma – practice in 2019

*Moderators: J.-F. Geschwind (Westport, CT/US),
R. Lencioni (Pisa/IT)*



- 401.1 Imaging of HCC: from EASL 2018 to LI-RADS
M. Ronot (Clichy/FR)
- 401.2 TACE: new concepts
B. Guiu (Montpellier/FR)
- 401.3 Is ablation only for non-surgical candidates?
L. Crocetti (Pisa/IT)
- 401.4 Determinants of survival after TACE in patients with HCC
J.-F. Geschwind (Westport, CT/US)
- 401.5 Ablation: how to select patients with best outcomes
A. Denys (Lausanne/CH)
- 401.6 Radioembolisation: is dosimetry the key?
M.G.E.H. Lam (Utrecht/NL)



e-voting



recommended for EBIR preparation

15:00-16:30, Auditorium II

Clinical Focus Session

CF 402 Other organs

*Moderators: T.K. Helmberger (Munich/DE),
T. Sabharwal (London/UK)*

402.1 Thyroid

R. Cervelli (Pisa/IT)

402.2 Pancreas

G. Narayanan (Miami, FL/US)

402.3 Adrenal

J. Garnon (Strasbourg/FR)

402.4 Lymph nodes

G. Tsoumakidou (Lausanne/CH)

402.5 Breast

J. Palussière (Bordeaux/FR)

15:00-16:30, Auditorium III (G 103)

Hands-on Device Training

TA-HDT 2 Tumour ablation – Radiofrequency

*Coordinators: J.M. Abadal (Madrid/ES),
F. Orsi (Milan/IT)*

17:00-18:30, Main Auditorium

Clinical Focus Session

CF 501 Colorectal

*Moderators: J.I. Bilbao (Pamplona/ES),
O.M. van Delden (Amsterdam/NL)*



501.1 Prognostic factors in metastatic cancer (not TNM)
J.-E. Kurtz (Strasbourg/FR)



501.2 Treatment strategies according to the ESMO
guidelines
D. Arnold (Hamburg/DE)

501.3 Immunotherapy in metastatic colorectal cancer:
when and how
M. Fuchs (Munich/DE)

501.4 Summary of "Ablation of colorectal liver
metastases: interaction of ablation margins
and RAS mutation profiling on local tumour
progression-free survival"
O.M. van Delden (Amsterdam/NL)



501.5 Local treatment in oligometastatic disease
M. Meijerink (Amsterdam/NL)



501.6 Intra-arterial therapies in liver-dominant disease
P.L. Pereira (Heilbronn/DE)



e-voting



recommended for EBIR preparation

17:00-18:30, Auditorium II



Technical Focus Session

TF 502 Tips and tricks: case-based discussion

*Moderators: F. Fanelli (Florence/IT),
M. Sone (Tokyo/JP)*

- 502.1 Painful bone metastases: HIFU or no HIFU?
A. Napoli (Rome/IT)
- 502.2 Central lung tumours: how to manage?
A. Veltri (Orbassano/IT)
- 502.3 How to treat sub-pleural lung disease?
F. Deschamps (Villejuif/FR)
- 502.4 T1b renal cancer: how to achieve complete response?
D.J. Breen (Southampton/UK)
- 502.5 Kidney ablation: difficult locations?
G.D. Schmit (Rochester, MN/US)

17:00-19:00, Auditorium III (G 103)

Basic Course

BC 503 Fundamentals in liver IO intervention



- 503.1 Imaging and biopsy of liver tumours: what an IO should know
R. Duran (Lausanne/CH)



- 503.2 Anatomy of liver arteries: tips and tricks for catheterism
J. Bell (Manchester/UK)



- 503.3 Ablation tools for liver tumours: RFA, cryo and microwave; multipolar and monopolar
C. van der Leij (Maastricht/NL)



- 503.4 Embolisation products: beads, lipiodol and others
L. Tselikas (Villejuif/FR)

18:30-19:15, Auditorium II

SY 601 Satellite Symposium

For the programme, please refer to page 65.

Tuesday, April 9

08:30-10:00, Main Auditorium

Clinical Focus Session

CF 801 Intrahepatic cholangiocarcinoma

*Moderators: P. Chevallier (Nice/FR),
U. Pua (Singapore/SG)*



801.1 Peripheral intrahepatic cholangiocarcinoma vs Klatskin tumour: epidemiology, biology and treatment concepts

A. Vogel (Hanover/DE)



801.2 Peripheral intrahepatic cholangiocarcinoma: the role of intra-arterial treatment

T.K. Helmberger (Munich/DE)



801.3 Peripheral intrahepatic cholangiocarcinoma in cirrhotic patients: the role of interventional oncology

A. Hocquelet (Lausanne/CH)

801.4 Surgical management of intrahepatic cholangiocarcinoma

T.M. van Gulik (Amsterdam/NL)



801.5 How to prepare the liver for surgery

O.M. van Delden (Amsterdam/NL)

Panel discussion

TUE



e-voting



recommended for EBIR preparation

08:30-10:00, Auditorium II

Clinical Focus Session

CF 802 Immunotherapy: actual clinical applications – what an IR should know

Moderators: E. Brountzos (Athens/GR)

G. Malouf (Strasbourg/FR),

802.1 Main immunotherapeutic drugs in 2019 – efficacy and side effects

U. Martens (Heilbronn/DE)

802.2 Immunotherapy in renal cell carcinoma – what's new in 2019?

A. Digkila (Lausanne/CH)

802.3 Immunotherapy in lung cancer

C. Ottensmeier (Southampton/UK)

802.4 Role of biopsies?

A.D. Bins (Amsterdam/NL)

802.5 Imaging of immune response: state-of-the-art and challenges

C. Dromain (Lausanne/CH)

10:30-11:30, Main Auditorium

HL 901 Honorary Lecture

Moderators: R.A. Morgan (London/UK),

O.M. van Delden (Amsterdam/NL)

Laudation: T. de Baère (Villejuif/FR)

901.1 Interventional oncology:

from Europe to South America

R.D. García-Mónaco (Buenos Aires/AR)

11:30-12:00, Main Auditorium

Free Paper Session

FP 902 Free Paper Session 1

*Moderators: R.A. Morgan (London/UK),
O.M. van Delden (Amsterdam/NL)*

- 902.1 Real-time biopsy system for combined optical spectroscopy and electromagnetic tracking in a woodchuck hepatocellular carcinoma model
Q.M.B. de Ruiter¹, S. Xu¹, M. Li¹, J. Karanian¹, A. Mikhail¹, M. Mauda Havakuk¹, P. Heidari², A. Sajjadi², W.F. Pritchard¹, U. Mahmood², B.J. Wood¹; ¹Bethesda, MD/US, ²Boston, MA/US
- 902.2 Augmented reality and artificial intelligence-based navigation during percutaneous vertebroplasty: a pilot prospective clinical study
P. Auloge¹, R.L. Cazzato¹, N. Ramamurthy², P. De Marini¹, C. Rousseau³, J. Garnon¹, Y.P. Charles¹, J.-P. Steib¹, A. Gangi¹; ¹Strasbourg/FR, ²Norwich/UK, ³Rennes/FR
- 902.3 Percutaneous electrochemotherapy of the pancreas is feasible and safe in a porcine survival model
R. Dezman, G. Serša, A. Seliskar, V. Erjavec, P. Popovič, B. Trotovec, G. Gašljevič, N. Boc, M. Bošnjak, U. Lamprecht Tratar, B. Kos, M. Djokic, M. Štabuc, J. Izlakar, N. Milevoj, M. Brložnik, M. Štukelj, B. Krhin, D. Miklavčič, M. Čemažar; Ljubljana/SI

10:30-12:00, Safe Sedation (G 107)

Hands-on Training

SED-HO 1 Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE),
W. Heinrichs (Mainz/DE)*



e-voting



recommended for EBIR preparation

10:30-12:00, Auditorium III (G 103)

Hands-on Device Training

TA-HDT 3 Tumour ablation – Microwave

*Coordinators: S. Ilyas (London/UK),
P.P. Rao (Colmar/FR)*

13:00-13:45, Main Auditorium

SY 1001 Satellite Symposium

For the programme, please refer to page 67.

13:45-14:30, Main Auditorium

SY 1002 Satellite Symposium

For the programme, please refer to page 69.

13:00-14:30, Safe Sedation (G 107)

Hands-on Training

SED-HO 2 Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE),
W. Heinrichs (Mainz/DE)*

15:00-16:30, Auditorium II

Clinical Focus Session

CF 1101 Lung metastases

*Moderators: J.-Y. Gaubert (Marseille/FR),
J. Palussière (Bordeaux/FR)*



1101.1 Rationale for local treatment

E.F. Smit (Amsterdam/NL)

1101.2 SBRT: curative or delayed growth

S. Heymann (Strasbourg/FR)

1101.3 Surgery: utility and limitations

J. Jougon (Pessac/FR)

1101.4 Lessons learned from scientific papers
on microwave ablation of lung tumours

J. Palussière (Bordeaux/FR)



1101.5 Management of oligometastatic patients:
non-colorectal

J.-Y. Gaubert (Marseille/FR)



1101.6 Management of oligometastatic patients:
colorectal

A. Gillams (London/UK)

TUE



e-voting



recommended for EBIR preparation

15:00-16:30, Main Auditorium

Clinical Focus Session

CF 1102 Colorectal liver metastases

*Moderators: M. Ducreux (Villejuif/FR),
T.F. Jakobs (Munich/DE)*



1102.1 The oncologist's point of view: the ESMO tool box
G. Masi (Pisa/IT)



1102.2 Radioembolisation: landmark clinical trials and patient selection
R. Sharma (London/UK)

1102.3 Lessons learned from Dr. Lemdani et al.:
Local immunomodulation combined to
radiofrequency ablation results in a complete
cure of local and distant colorectal carcinoma
T.F. Jakobs (Munich/DE)

1102.4 Hepatic arterial infusion chemotherapy (HAIC):
patient and drug selection
M. Ducreux (Villejuif/FR)



1102.5 Ablation vs surgery for oligometastatic disease:
evidence
C.T. Sofocleous (New York, NY/US)

1102.6 TACE for colorectal mets: updated results
J. Golzarian (Minneapolis, MN/US)

15:00-16:30, Safe Sedation (G 107)

Hands-on Training

SED-HO 3 Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE),
W. Heinrichs (Mainz/DE)*

15:00-16:30, Auditorium III (G 103)

Hands-on Device Training

TA-HDT 4 Tumour ablation – Microwave

*Coordinators: S. Ilyas (London/UK),
P.P. Rao (Colmar/FR)*

17:00-18:30, Main Auditorium

Clinical Focus Session

CF 1201 SBRT of liver and lung tumours understanding mechanisms and limitations

*Moderators: J.-E. Kurtz (Strasbourg/FR),
S.B. Solomon (New York, NY/US)*

- 1201.1 Radiobiology: sensitive and resistant tumours
L.M. Kenny (Brisbane, QLD/AU)
- 1201.2 SBRT for liver and lung tumours: the radiotherapist's perspective
M. Hawkins (Oxford/UK)
- 1201.3 Response assessment: liver and lung
R.D. Suh (Los Angeles, CA/US)
- 1201.4 SBRT of lung tumours: the limitations
S. Heymann (Strasbourg/FR)
- 1201.5 Ablation of lung tumours: the limitations
T. de Baère (Villejuif/FR)




Panel discussion

17:00-18:30, Auditorium II

Clinical Focus Session

CF 1202 MSK: curative treatment

*Moderators: X. Buy (Bordeaux/FR),
A. Kelekis (Athens/GR)*

-  1202.1 Essentials of biopsy in MSK tumours
A. Feydy (Paris/FR)
- 1202.2 How to be curative in primary tumours: which IO treatment and where?
J.W. Jennings (Saint Louis, MO/US)
-  1202.3 How to avoid complications?
M.R. Callstrom (Rochester, MN/US)
-  1202.4 Role of IO in oligometastatic bone disease
D. Filippiadis (Athens/GR)
- 1202.5 Multimodality treatment for cure in bone tumours
R.-T. Hoffmann (Dresden/DE)



e-voting



recommended for EBIR preparation

17:00-19:00, Auditorium III (G 103)

Basic Course

BC 1203 Ablation and TACE of liver tumours



1203.1 Ablation of primary liver tumours: good indications and methods

C. van der Leij (Maastricht/NL)



1203.2 Ablation of metastatic liver tumours: when ablation should replace surgery

L. Tselikas (Villejuif/FR)



1203.3 TACE of HCC: how to make it and how to manage the patient

R. Duran (Lausanne/CH)



1203.4 TACE and ablation complications: how to recognise and manage them

J. Bell (Manchester/UK)

TUE

18:30-19:15, Meeting Room I (G 110)

SY 1301 Satellite Symposium

For a detailed programme, please refer to page 71.

Wednesday, April 10

08:30-10:00, Main Auditorium

Clinical Focus Session

CF 1501 Kidney cancer – current controversies

Moderators: E. de Kerviler (Paris/FR),

D.A. Gervais (Boston, MA/US)



1501.1 Guidelines: from an IO perspective

D.A. Gervais (Boston, MA/US)

1501.2 Understanding malignant potential with biopsy – histological viewpoint

S. Fleming (Dundee/UK)

1501.3 Lessons learned from experimental studies to optimise cryoablation protocols

E. de Kerviler (Paris/FR)



1501.4 Ablation: which energy when?

G.D. Schmit (Rochester, MN/US)

1501.5 Ablation in the era of robotic partial nephrectomy: surgical perspective

A. Bex (Amsterdam/NL)



1501.6 Ablation in the era of robotic partial nephrectomy: IO perspective

D.J. Breen (Southampton/UK)

08:30-10:00, Auditorium II

Clinical Focus Session

CF 1502 Immunotherapy: where are we heading (research)

Moderators: U. Martens (Heilbronn/DE),

B.J. Wood (Bethesda, MD/US)

1502.1 HIT-IT (human intratumoural immunotherapy):

ESMO recommendations

T. de Baère (Villejuif/FR)

1502.2 Drugs for intratumoural injection

S. Champiat (Villejuif/FR)

1502.3 Intratumoural viral injections: concepts and results

1502.4 Priming immune response with ablation

S.N. Goldberg (Jerusalem/IL)

1502.5 Liquid biopsies

R. Corcoran (Boston, MA/US)



e-voting



recommended for EBIR preparation

08:30-10:00, Safe Sedation (G 107)

Hands-on Training

SED-HO 4 Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE),
W. Heinrichs (Mainz/DE)*

10:30-12:00, Main Auditorium

Clinical Focus Session

CF 1601 Cancer pain management

*Moderators: D. Filippiadis (Athens/GR),
S. Masala (Rome/IT)*

1601.1 Systemic therapies for bone metastases

A. Antonuzzo (Pisa/IT)



1601.2 IO and/or radiotherapy: when and where

S. Marcia (Cagliari/IT)

1601.3 Nerve blocks and neurolysis

A.D. Kelekis (Athens/GR)



1601.4 Bone metastases: thermal ablation with or without consolidation

U. Pua (Singapore/SG)

1601.5 Embolisation in pain palliation in MSK tumours

R. García Marcos (Valencia/ES)

1601.6 Percutaneous consolidations: cement, screw...

R.-T. Hoffmann (Dresden/DE)



10:30-12:00, Auditorium II

Clinical Focus Session

CF 1602 Emergency in oncology

*Moderators: R. Iezzi (Rome/IT),
A.G. Ryan (Waterford City/IE)*



1602.1 Head and neck bleeding

A. Hakimé (Villejuif/FR)



1602.2 Haemoptysis

R. Cioni (Pisa/IT)



1602.3 How to manage ruptured HCC

J. Urbano (Madrid/ES)



1602.4 Superior vena cava syndrome

W. Prevoo (Amsterdam/NL)



1602.5 Abdominal and pelvic bleeding

A.G. Ryan (Waterford City/IE)

10:30-12:00, Safe Sedation (G 107)

Hands-on Training

SED-HO 5 Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE),
W. Heinrichs (Mainz/DE)*

10:30-12:00, Auditorium III (G 103)

Hands-on Device Training

TA-HDT 5 Tumour ablation – Cryoablation and laser ablation

*Coordinators: F.M. Gómez (Barcelona/ES),
A.H. Mahnken (Marburg/DE)*



e-voting



recommended for EBIR preparation

13:00-13:45, Main Auditorium

SY 1701 Satellite Symposium

For the programme please refer to page 73.

13:45-14:30, Main Auditorium

SY 1702 Satellite Symposium

For the programme please refer to page 73.

13:00-14:30, Safe Sedation (G 107)

Hands-on Training

SED-HO 6 Safe sedation application during IR procedures

*Coordinators: M. Heinrichs (Mainz/DE),
W. Heinrichs (Mainz/DE)*

15:00-16:30, Main Auditorium

Multidisciplinary Tumour Board

MTB 1801 MSK

*Coordinators: M.R. Callstrom (Rochester, MN/US),
S. Masala (Rome/IT)*

*Panellists: M. Borensztein (Buenos Aires/AR),
J. Garnon (Strasbourg/FR),
J.W. Jennings (Saint Louis, MO/US),
A.N. Kurup (Rochester, MN/US),
P.J. Papagelopoulos (Athens/GR)*

15:00-16:30, Auditorium II

Video Learning Session

VL 1802 How I do it

*Moderators: P. Chevallier (Nice/FR),
W. Prevoo (Amsterdam/NL)*

- 1802.1 Liver – triple preparation technique for extended resection of Klatskin tumour
B. Guiu (Montpellier/FR)
- 1802.2 Lung – difficult locations
F. Deschamps (Villejuif/FR)
- 1802.3 Liver – guidance and targeting for ablation
G. Tsoumakidou (Lausanne/CH)
- 1802.4 Liver – solving complex anatomical problems in TACE
I. Bargellini (Pisa/IT)
- 1802.5 Bone – pinning and stabilisation
X. Buy (Bordeaux/FR)
- 1802.6 Kidney – T1b
T.D. Atwell (Rochester, MN/US)

15:00-16:30, Auditorium III (G 103)

Hands-on Device Training

TA-HDT 6 Tumour ablation – Image guidance

*Coordinators: A. Hakimé (Villejuif/FR),
L. Solbiati (Rozzano/IT)*



e-voting



recommended for EBIR preparation

17:00-18:30, Main Auditorium

Clinical Focus Session

CF 1901 Response assessment and follow-up imaging

*Moderators: L. Crocetti (Pisa/IT),
K. Malagari (Athens/GR)*



1901.1 Ablation for MSK tumours

A. Feydy (Paris/FR)



1901.2 TACE

Y. Arai (Tokyo/JP)



1901.3 Radioembolisation

R. Salem (Chicago, IL/US)



1901.4 Thermal ablation for lung cancer

R.D. Suh (Los Angeles, CA/US)



1901.5 Thermal ablation for renal cancer

N. Patel (London/UK)

Panel discussion

WED

17:00-18:30, Auditorium II

Free Paper Session

FP 1902 Free Paper Session 2

Moderators: M. Meijerink, Amsterdam/NL

H. Rio Tinto (Lisbon/PT)

- 1902.1 Percutaneous irreversible electroporation to treat locally advanced pancreatic cancer: the PANFIRE-2 trial final results
A. Ruarus, L. Vroomen, R. Puijk, M. de Jong, B. Zonderhuis, M.G.H. Besselink, M.P. van den Tol, G. Kazemier, H. Scheffer, M. Meijerink; Amsterdam/NL
- 1902.2 Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for anti-tumor T-cell activation
H. Scheffer, A. Stam, L. Vroomen, B. de Bruijn, P. van den Tol, G. Kazemier, M. Meijerink, T. de Gruij; Amsterdam/NL
- 1902.3 Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE: a single-center, interventional, non-randomized, non-comparative, open-label, phase II study (HEPAR PLUS trial)
A.J.A.T. Braat¹, R. van Rooij¹, R. Bruijnen¹, R.S. van Leeuwen¹, W.W. de Herder², M. Tesselaar³, H.W.A.M. de Jong¹, M.G.E.H. Lam¹; ¹Utrecht/NL, ²Rotterdam/NL, ³Amsterdam/NL
- 1902.4 Percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System's second-generation hemofiltration system: a prospective phase II study
T.S. Meijer, M.C. Burgmans, B. Boekstijn, A.R. van Erkel, L.-F. de Geus-Oei, H. Handgraaf, D.E. Hilling, E.M. de Leede, J. Lutjeboer, C.H. Martini, R.W. van der Meer, E.M. Sitsen, F.M. Speetjens, F.G.J. Tijl, E. Kapiteijn, A.L. Vahrmeijer; Leiden/NL



e-voting







recommended for EBIR preparation

- 1902.5 Prospective and multicentric evaluation of 100-μ DEB-TACE in patients with non-resectable HCC
J. Urbano¹, J. Echevarria-Uraga², J.J. Ciampi-Dopazo³,
J. Sanchez Corral¹, B. Peña Baranda², V. Nacarino⁴,
R. González Costero¹, J.J. Muñoz Ruiz-Canela⁵,
J. Cuesta Pérez¹, L. López Carreira⁶; ¹Madrid/ES,
²Bilbao/ES, ³Toledo/ES, ⁴Sevilla/ES, ⁵Málaga/ES,
⁶Lugo/ES
- 1902.6 Dose-effect relationship for hepatic holmium-166 radioembolization in colorectal cancer patients
C. van Roekel, R. Bastiaannet, M. Smits, S. Elias,
R. Bruijnen, J. Prince, H. de Jong, M.G.E.H. Lam;
 Utrecht/NL
- 1902.7 RFA vs robotic partial nephrectomy for T1a renal cell carcinoma: a propensity score-matched comparison of mid-term outcome
B.K. Park; Seoul/KR
- 1902.8 Therapeutic outcomes of thermal ablation for endophytic vs exophytic renal cell carcinoma
W. Zhou, S. Herwald, R. Arellano; Boston, MA/US
- 1902.9 Transarterial embolization of prostate with biodegradable flutamide-loaded PLA/PLGA microspheres for benign prostate hyperplasia: preliminary study in normal swine model
F. Nurili¹, T. Acar², S. Derman², I. Yurdaisik², A. Bas²,
H. Cakiroglu³, S. Ozkanli², O. Aras¹; ¹New York, NY/US,
²Istanbul/TR, ³Adapazari/TR
- 1902.10 An ex vivo bench and perfused liver assessment and extension of the ablation zone by "EdgeBoost" with IR-Circle: a new bipolar ablation device
K.H. Altoukhi, J. Akhter, A. Mekkawy, N.A. Alzahrani,
S.J. Valle, D.L. Morris; Sydney, NSW/AU

17:00-19:00, Auditorium III (G 103)

Basic Course

BC 1903 Radioembolisation

-  1903.1 Currently available tools: resin glass, Yttrium, Holmium and others
R. Duran (Lausanne/CH)
-  1903.2 Dosimetry for radiologists: understanding the dose
J. Bell (Manchester/UK)
-  1903.3 Radioembolisation in HCC patients: good indications and good practice
C. van der Leij (Maastricht/NL)
-  1903.4 Radioembolisation out of HCC: CRC, ICC, melanoma and others...
L. Tselikas (Villejuif/FR)



e-voting



recommended for EBIR preparation

Thursday, April 11

08:30-10:00, Auditorium II

Clinical Focus Session

CF 2101 New indications: localised prostate cancer

*Moderators: X. Cathelineau (Paris/FR),
J.J. Fütterer (Nijmegen/NL)*

- 2101.1 Natural history of localised prostate cancer
R. Popert (London/UK)
- 2101.2 Imaging gland disease
S.W.T.P.J. Heijmink (Amsterdam/NL)
- 2101.3 Biopsy of prostate: when and how
R. Popert (London/UK)
- 2101.4 Surgery or radiotherapy: which is the standard of care?
X. Cathelineau (Paris/FR)
- 2101.5 IO options for localised disease
J.J. Fütterer (Nijmegen/NL)

08:30-10:00, Main Auditorium

Clinical Focus Session

CF 2102 Quality issues, research and patterns of practice in interventional oncology

*Moderators: A. Adam (London/UK),
L.M. Kenny (Brisbane, QLD/AU)*

- 2102.1 The role of IR in a centre of excellence in cancer care
C.T. Sofocleous (New York, NY/US)
- 2102.2 Research in IO – the potential synergy with radiation oncology
N.I. Brown (Brisbane, QLD/AU)
- 2102.3 An exemplar of collaboration in the treatment of lung cancer: heat, photons or both?
S.B. Solomon (New York, NY/US)
- 2102.4 Quality assurance – the key to front-line status in oncology
L.M. Kenny (Brisbane, QLD/AU)

Panel discussion



10:30-12:00, Main Auditorium

MM 2201 Morbidity & Mortality Conference

*Coordinators: M. Burrel (Barcelona/ES),
J. Golzarian (Minneapolis, MN/US)*

- 2201.1 Avoiding complications in renal ablations
M. Borensztein (Buenos Aires/AR)
- 2201.2 Large retroperitoneal tumour: ablation feasible?
R. Freitas (Sao Paulo/BR)
- 2201.3 IRE ablation of superficial HCC; think first
F. Holmquist, A. Nilsson (Lund/SE)
- 2201.4 Complications of a long term biliary drain
in the context of pancitopenic patient
A. Olavarria Delgado (Madrid/ES)
- 2201.5 Hepatic artery pseudoaneurysm after
trans arterial chemoembolisation
M. Burrel (Barcelona/ES)

THU



e-voting




recommended for EBIR preparation



ECIO 2020

European Conference
on Interventional Oncology

April 26-29, 2020
Nice, France



LEADERS IN ONCOLOGIC
INTERVENTIONS



Cardiovascular and Interventional Radiological Society of Europe

Posters

ECIO 2019 Posters will be presented electronically in the Poster Area throughout the congress.

Due to withdrawn abstracts, certain numbers are missing.

Kidney

- P-1 Safety of percutaneous renal cryoablation: an international multicentre experience from the EuRECA retrospective database
J. Garnon¹, D.J. Breen², A. King², B. Lagerveld³, M.J.L. van Strijen⁴, T. Nielsen⁵, F. Keeley⁶; ¹Strasbourg/FR, ²Southampton/UK, ³Amsterdam/NL, ⁴Nieuwegein/NL, ⁵Aarhus/DK, ⁶Bristol/UK
- P-2 A web-based and user-friendly planning tool to predict outcome for percutaneous cryoablation of renal tumours including validation of the simulation model
T.J. van Oostenbrugge¹, J. Heidkamp¹, P. Voigt², M. Moche², P. Weir³, P. Mariappan³, R. Flanagan³, M. Pollari⁴, S. Payne⁵, R. Ellerweg⁶, M. Kolesnik⁶, H. Langenhuijsen¹, S. Jenniskens¹, J.J. Fütterer¹; ¹Nijmegen/NL, ²Leipzig/DE, ³Dublin/IE, ⁴Helsinki/FI, ⁵Oxford/UK, ⁶Sankt Augustin/DE
- P-3 What could be the optimal type of embolic agent and interval for transarterial embolization (TE) prior to CT-guided thermal ablation (TA) of renal tumors? – histopathologic considerations on the basis of pre-operative renal tumor embolization data
C.M. Sommer¹, G.M. Richter², F. Pan¹, D.F. Vollherbst¹, T.D. Do¹, P.L. Pereira³, H.U. Kauczor¹, K. Kriegsmann¹, G. Hatiboglu¹, M. Kriegsmann¹; ¹Heidelberg/DE, ²Stuttgart/DE, ³Heilbronn/DE
- P-4 Percutaneous thermoablation of small renal masses (T1a) in surgical candidate patients: oncologic outcomes
R.N. Zangiacomo, G.L.P. Martins, P.C.C. Viana, M.A. Arap, W. Nahas, M. Srougi, G.G. Cerri, M.R. Menezes; São Paulo/BR

- P-5 Safety and oncologic efficacy using an innovative liquid nitrogen-based cryogenic device in SRMs
T.L. Gasper¹, R. Sachner¹, S. Croitoru¹, K. Dorfman¹, Y. Halpern¹, S. Shprits¹, O. Avitan¹, Z. Bahouth¹, O. Nativ¹, A. Zisman²; ¹Haifa/IL, ²Be'er Ya'akov/IL
- P-6 A comparative evaluation of procedural and therapeutic outcomes of thermal ablation for T1b vs T1a renal cell carcinoma
W. Zhou, S. Herwald, R. Arellano; Boston, MA/US
- P-7 Image-guided thermal ablation for renal cell cancer: evaluation of long-term oncological outcomes in patients with at least 5 years of follow-up
W. Zhou, S. Herwald, R. Arellano; Boston, MA/US

Liver

- P-8 Comparison of four different transarterial regimens for treatment of hepatocellular carcinoma – a retrospective study
A. Almat'hami¹, H. Alobaidi¹, Y. Alzahrani¹, R. Zener², D. Wiseman², A. Mujoomdar²; ¹Riyadh/SA, ²London, ON/CA
- P-9 Coaxial liver biopsy vs. direct puncture for liver biopsy: a retrospective cohort study
R. Varela Ponte¹, N. Martinez Lago², M. Vieito Villar³, J.M. Carreira Villamor¹; ¹Santiago De Compostela/ES, ²A Coruña/ES, ³Barcelona/ES
- P-10 Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation vs rhenium transarterial radioembolisation alone in patients with a large solitary or multinodular hepatocellular carcinomas
B.R. Raveendran Sheela; Kochi/IN
- P-11 Intermediate/advanced HCC/SIRT and balloon-occlusive microcatheter: the right way?
A. Paladini¹, G.E. Vallati², G. Pizzi², F. Cappelli²; ¹Novara/IT, ²Rome/IT

- P-12 Response to SIRT (Selective Internal Radiation Therapy) in patients affected by unresectable multifocal intra-hepatic cholangiocarcinoma: results of a preliminary study
A. Paladini¹, G.E. Vallati², G. Pizzi², F. Cappelli²;
¹Novara/IT, ²Rome/IT
- P-13 Health-related quality of life evaluation in "left" versus "right" access for percutaneous transhepatic biliary drainage using EORTC QLQ-BIL-21 questionnaire
D.G. Castiglione¹, C. Gozzo¹, G. Caltabiano², S. Palmucci², A. Basile², A. Musumeci², L. Mammino²; ¹Palermo/IT, ²Catania/IT
- P-14 Propofol vs midazolam sedation for percutaneous radiofrequency (RFA) and microwave ablation (MWA) in patients with hepatic malignancies: a single-center comparative analysis of two historical cohorts
R. Puijk, V. Ziedses des Plantes, S. Nieuwenhuizen, A. Ruars, L. Vroomen, M. de Jong, B. Geboers, C. Hoedemaker-Boon, D. Thöne-Passchier, C. Gerçek, J. de Vries, H. Scheffer, P. van den Tol, M. Meijerink; Amsterdam/NL
- P-15 Major impact of personalised dosimetry on the targeted tumor response using 90Y loaded glass microspheres SIRT in HCC: results of a prospective and multicentric randomized study
E. Garin¹, L. Tselikas², B. Guiu³, J. Chalaye⁴, J. Edeline¹, S. Laffont¹, T. de Baère², C. Cassinotto³, T. Tacher⁴, M. Terroir-Cassou-Mounat¹, F. Ben Bouallègue³, G. Amadeo⁴, X. Palard¹, B. Campillo-Gimenez¹, Y. Rolland¹; ¹Rennes/FR, ²Villejuif/FR, ³Montpellier/FR, ⁴Créteil/FR
- P-16 Ablation of colorectal liver metastases by irreversible electroporation: final results of the COLDFIRE-2 trial
M. Meijerink, A. Ruars, L. Vroomen, R. Puijk, B. Geboers, J. de Vries, K. Nielsen, G. Kazemier, K. van Lienden, P. van den Tol, H. Scheffer; Amsterdam/NL

- P-17 Combined percutaneous microwave ablation (MWA) and transarterial chemoembolization (TACE) for hepatocellular carcinoma
G. Poggi, B. Montagna, I. Palumbo, L. Franchi Bononi; Pavia/IT
- P-18 Pharmacokinetic analyses in patients with unresectable hepatocellular carcinoma treated by TACE with doxorubicin drug-eluting microspheres
K. Malagari¹, M. Burrel², M. Reig², R. Duran³, A. Digklia³, A. Denys³, M. Brunet², J. Bruix²; ¹Athens/GR, ²Barcelona/ES, ³Lausanne/CH
- P-19 Treatment of unresectable HCC with doxorubicin-eluting microspheres: a single-center experience
G.A. Tovar¹, J. Sempere¹, A. García Gámez¹, V. Benito Santamaría¹, D. Balaguer¹, J. Villalba²; ¹Badalona/ES, ²Barcelona/ES
- P-20 Percutaneous stereotactic CT-based microwave ablation for neuroendocrine liver metastasis
M. Maurer, A. Lachenmayer, G. Beldi, D. Candinas, C. Kim-Fuchs; Bern/CH
- P-21 Chemosaturation percutaneous hepatic perfusion (CS-PHP) with Melphalan: evaluation of 2D-perfusion angiography (2D-PA) as a tool to detect leakage of venous double-balloon catheter
C.L.A. Dewald, S.K. Maschke, T.C. Meine, J. Renne, M. Kirstein, F. Wacker, B. Meyer, J.B. Hinrichs; Hanover/DE
- P-22 Stereotactic image-guided microwave ablation for malignant liver tumors: can computer-assistance broaden treatment eligibility?
P. Tinguely, A. Lachenmayer, V. Banz, S. Weber, D. Candinas, M. Maurer; Bern/CH

- P-23 LifePearl® Anthracyclin Registry in selective chemo-embolization of patients with unresectable hepatocellular carcinoma: PARIS study preliminary results
T. de Baère¹, L. Tselikas¹, G. Verset², B. Guiu³, M. Ronot⁴, P. Chevallier⁵, G. Sergent⁶, P. Goffette²; ¹Villejuif/FR, ²Brussels, BE, ³Montpellier/FR, ⁴Clichy/FR, ⁵Nice/FR, ⁶Lille/FR
- P-24 Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation vs transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinoma
L. Zheng, H.L. Li, C.Y. Guo; ZhengZhou/CN
- P-25 Analysis of risk factors for survival after TIPS for variceal bleeding
M.B. Pitton, J. Moehricke, S. Schotten, T. Zimmermann, J. Mittler, C. Düber; Mainz/DE
- P-26 Predictive factors of survival after TIPS for refractory ascites in end-stage liver disease
M.B. Pitton, M. Moddemann, S. Schotten, J. Mittler, T. Zimmermann, R. Kloeckner, C. Düber; Mainz/DE
- P-27 A resident's guide to hepatic venous pressure measurement: utility, technique, pitfalls and outcome studies
A. Mai, P. Cramer, T. Braaten, A. Pillai; Houston, TX/US
- P-28 Usefulness and safety of biliary percutaneous transluminal forceps biopsy in diagnosis of malignant biliary obstruction: single-centre experience
F. Corvino, F. Giurazza, M. Silvestre, G. Cangiano, E. Cavaglia, A. Corvino, R. Niola; Naples/IT
- P-29 Percutaneous electrochemotherapy of hepatocellular carcinoma at hepatic hilum
L. Tarantino¹, A. Nasto¹, G. Busto¹, R. Fristachi¹, L. Cacace¹, P. Tarantino², R.A. Nasto³, S. Bortone¹, M.R. Romano¹, M. Fabozzi¹; ¹Pagani/IT, ²Milan/IT, ³Naples/IT

- P-30 CEUS monitoring of intratumoral microcirculation after electroporation of liver tumors
L. Tarantino; Pagani/IT
- P-31 Survival, tumour response, safety and prognostic factors 70-150µm versus 100-300µm particles for Doxorubicin drug-eluting bead TACE in patients with unresectable hepatocellular carcinoma: a four-year Australian experience
Y.R. Huo, H. Xiang, M.V. Chan, C. Chan; Sydney, NSW/AU
- P-32 Predictive factors of complete response of hepatic transarterial chemoembolizations with drug eluting beads in patients with hepatocellular carcinoma
L.S. Alberton, L.G.M. Valle, G.G. Moratti, P.M. Falsarella, R.B. Martins, V.D.O. Carvalho, C.A. Lima, L. Lembrança, J.M.M. Leal Filho, F.L. Galastrri, B.B. Affonso, F. Nasser; São Paulo/BR
- P-33 Five-year survival post chemoembolization with HepaSphere 30.60 for HCC not amenable to curative treatments
K. Malagari¹, H. Moschouris², T. Kiakidis¹, S. Howard³, A.D. Kelekis¹, D. Filippiadis¹, A. Chatziioannou¹, V. Vergadis¹, E. Brountzos¹, N. Kelekis¹; ¹Athens/GR, ²Pireus/GR, ³Boston, MA/US
- P-34 Percutaneous radiofrequency ablation for hepatic tumors: factors affecting baseline impedance
J.W. Seo, S. Hwang; Goyang-Si/KR
- P-35 Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-eluting microsphere: 3-6 months oncological results
P. Lucatelli, G. de Rubeis, L. Ginanni Corradini, B. Rocco, A. Cannavale, P. Nardis, M. Corona, M. Bezzi; Rome/IT
- P-36 Uncommon radiologic findings that happened in the RFA sites in the liver
Y.M. Shin, S.J. Lee, S.Y. Kim, H.J. Won, P.N. Kim; Seoul/KR

- P-37 Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath System's second-generation hemofiltration system: a prospective non-randomized phase II study
T.S. Meijer, M.C. Burgmans, M. Fiocco, L.-F. de Geus-Oei, E. Kapiteijn, E.M. de Leede, C.H. Martini, R.W. van der Meer, F.G.J. Tijl, A.L. Vahrmeijer; Leiden/NL
- P-38 Intra-arterial peptide receptor radionuclide therapy for neuroendocrine tumor liver metastases
S.C. Ebbers, M.W. Barentsz, A.J.A.T. Braat, M.G.E.H. Lam; Utrecht/NL
- P-39 Chemoembolization using polyethylene glycol (PEG)-embolizing microspheres loaded with anthracyclines in HCC: predictive factors of response and efficacy evaluation
A.-M. Bucalau, I. Tancredi, R. Leveque, M. Pezzullo, G. Verset; Brussels/BE
- P-40 Efficacy of the radioembolic treatment of "large" monofocal hepatocarcinoma in BCLC A-stage patients: monocentric experience
A. Vit, T. Gorgatti, V. Gavrilovic, A. Pellegrin, F. Rosella, M. Sponza; Udine/IT
- P-41 The value of MDCT three-dimensional vascular remodeling in TACE for HCC
T. Qiang; Nanchang/CN
- P-42 Balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres (B-DEM-TACE) for hepatocellular carcinoma: a prospective monocentric study of safety, feasibility and early outcomes
G. Verset, A.-M. Bucalau, M. Pezzullo, R. Leveque, I. Tancredi; Brussels/BE

- P-43 Pain scores during continuous and pulsed mode of microwave ablation in the liver: a comparative study
M. Tsitskari, D. Filippiadis, G. Velonakis, L. Reppas, A.D. Kelekis, E. Brountzos, N. Kelekis; Athens/GR
- P-44 Y-90 radioembolization in advanced-stage HCC: does portal vein thrombosis affect survival?
F. Somma, V. Stoia, R. D'Angelo, F. Fiore; Naples/IT
- P-45 Portal vein embolisation (PVE) – anatomical considerations and embolisation techniques to achieve maximum FLR hypertrophy
C.L. Bent, A. Shawyer; Bournemouth/UK
- P-46 Holmium-166 radioembolization (Ho166-RE) in HCC: 12-month follow-up and outcome data
C.G. Radosa¹, J.C. Radosa², S. Grosche-Schlee¹, K. Zöphel¹, V. Plodeck¹, J.P. Kühn¹, R.-T. Hoffmann¹; ¹Dresden/DE, ²Homburg/DE
- P-47 Biopsy of suspect intrahepatic power of Lipiodol-enhancement in CT-guided biopsies of unspecified suspect intrahepatic lesions: improvement of accuracy and safeness
M.C. Langenbach, T.J. Vogl, A. Buchinger, L.M. Basten, R. Hammerstingl, T. Gruber-Rouh; Frankfurt/DE
- P-48 Treatment options for intermediate (3-5cm) unresectable colorectal liver metastases (CRLM): stereotactic ablative body radiotherapy (SABR) vs microwave ablation (MWA) – a comparative review
S. Nieuwenhuizen, R. Puijk, B. Geboers, A. Ruarus, N. Haasbeek, A. Bruynzeel, M.P. van den Tol, M. Meijerink; Amsterdam/NL
- P-49 Comparison of microwave and radiofrequency ablation for the treatment of liver metastases: randomized prospective study (MIRA study)
T.J. Vogl, Y. Jaraysa, S. Martin, A. Mehmedovic, N.-E. Nour-Eldin, T. Gruber-Rouh, R. Hammerstingl; Frankfurt/DE

Lung

- P-50 CT-guided pulmonary nodule microcoil localization
S.R. Alharbi; Riyadh/SA
- P-51 CT-guided lung biopsy using a 20-gauge needle biopsy: is it possible to obtain sufficient material for genetic analysis?
C.A. Lima, J.R. de Andrade, L.G.M. Valle, P.M. Falsarella, L.L. Pinheiro, G.M. Gilberto, V.D.O. Carvalho, G.F. Mendes, P.R.B. Silverio, F.A.C. Vieira, A.R. Junior, L.R. Socolowski, R.G. Garcia; São Paulo/BR
- P-52 Interventional PET-CT for lung and mediastinal tumours biopsy planning
M. Cherkashin, N. Berezina, D. Puchkov, D. Kuplevatskaya; St. Petersburg/RU
- P-53 Pneumothorax and pulmonary hemorrhage after CT-guided lung biopsy: incidence, clinical significance and correlation
V. Sabatino, U. Russo, F.V. D'Amuri, A. Bevilacqua, F. Pagnini, G. Milanese, R. Nizzoli, G. Pedrazzi, M. De Filippo; Parma/IT
- P-55 Outcome of ablation of 5-7 ipsilateral lung metastases at a single ablation session
A. Gillams¹, S. Smith²; ¹London/UK, ²Ipswich/UK
- P-56 Comparison between CBCT and fusion PET/CT-CBCT guidance for lung biopsies
A. Muollo¹, A. Beneventi¹, N. Casamassima¹, E. Macchi¹, F. Piacentino¹, F. Fontana¹, C. Floridi², C. Fugazzola¹, G. Carrafiello²; ¹Varese/IT, ²Milan/IT
- P-57 Radiofrequency and microwave ablation of soft-tissue sarcoma lung metastases: safety and oncological outcomes
T. Glover, N. Butterfield, N. Khan, C. Benson, J. McCall, R. Jones, N. Fotiadis; London/UK

Musculoskeletal

- P-58 Overview of percutaneous radiofrequency ablation for the treatment of osteoid osteomas
M.A.O. Kasem; Cairo/EG
- P-59 Osteoid osteoma treated with radiofrequency ablation in non-operating room anesthesia: our experience in 61 cases
A. Paladini¹, F. Cappelli², D. Beomonte Zobel², G.E. Vallati², G. Pizzi²; ¹Novara/IT, ²Rome/IT
- P-60 Rapid pain improvement in patients treated for painful bone metastases with the Medtronic OsteoCool RF ablation system: the OPuS One study
S. Bagla¹, J. Levy², T. Hopkins³, F. Massari⁴, A. Vogel⁵, A. Bress⁶, R. Dixon⁷, J. Mitchell⁸, P. Sunenshine⁹, J. Barr¹⁰, N. Tran¹¹, J. Morris¹², H. Berrier¹³, T. Brelje¹³, K. Schwartz¹³; ¹Woodbridge, VA/US, ²Cumming, GA/US, ³Durham, NC/US, ⁴Worcester, MA/US, ⁵Reno, NV/US, ⁶Fullerton, CA/US, ⁷Chapel Hill, NC/US, ⁸Atlanta, AL/US, ⁹Phoenix, AZ/US, ¹⁰Dallas, TX/US, ¹¹Tampa, FL/US, ¹²Rochester, MN/US, ¹³Fridley, MN/US
- P-61 Effect of transarterial bland embolization of renal cell carcinoma bone metastases on systemic biomarkers of tumor immunity: can tumor embolization affect immunotherapy response?
R. AlHalawani, R. Sheth, S. Yevich; Houston, TX/US

Novel therapies

- P-62 Tunnelled, non-cuffed internal jugular catheter in oncological patients for short- to mid-term vascular access: an interim report of an off-label application of the PICC
X.Z. Low, C.W. Too, A. Patel, A. Gogna, R. Lo, K. Damodharan, S. Chan, S. Chandramohan, S. Leong, N. Kumar, J. Chua, K.D. Zhuang, F.G. Irani; Singapore/SG

- P-63 A phase I/II study of direct injection of Bromelain and Acetylcysteine in patients with inoperable mucinous peritoneal tumours
S.J. Valle, J. Akhter, D. Glenn, M.A. Power, S. Lodh, W.S. Liauw, K.H. Altoukhi, D.L. Morris; Sydney, NSW/AU
- P-65 Pulsed electrical fields in oncology: reversible and irreversible electroporation, electrochemotherapy, electrogenotherapy and electrotransfection
B. Geboers¹, H. Scheffer¹, A. Ruarus¹, S. Nieuwenhuizen¹, R. Puijk¹, T. de Gruijl¹, D. Miklavčič², B. Rubinsky³, R.V. Davalos⁴, M. Meijerink²; ¹Amsterdam/NL, ²Ljubljana/SI, ³Berkeley, CA/US, ⁴Blacksburg, VA/US
- P-66 Abscopal effect of immunostimulating laser thermotherapy on liver metastasis in pancreatic cancer: a case report and study protocol for a randomised controlled trial
B. Gonçalves, M.J. Sousa, M. Machado, L. Santos; Porto/PT

Other organs

- P-67 Percutaneous endobiliary radiofrequency ablation (PE-RFA) combined with biliary stenting for palliation of malignant biliary obstruction: feasibility, safety and early results
C. Sallemi¹, L. Monfardini¹, M. Calandri², E. Soncin², D. Righi², P. Fonio²; ¹Brescia/IT, ²Turin/IT
- P-68 Radiofrequency ablation of primary parathyroid adenoma: preliminary results for patients ineligible for surgery
E.J. Ha; Suwon/KR
- P-69 Pancreaticoduodenal arcade as a challenging but effective alternate route for performing TACE in patients with unfavorable celiac axis anatomy
A. Johri, B.J. Amos, A. Burdette; Hershey, PA/US

- P-70 Intrahepatic Mitomycin C infusion in liver dominant metastatic breast cancer: factors influencing outcome
B.M. Aarts¹, E.G. Klompenhouwer¹, R.C. Dresen², A. Laenen², R.G.H. Beets-Tan¹, K. Punie², P. Neven², H. Wildiers², G. Maleux²; ¹Amsterdam/NL, ²Leuven/BE
- P-71 Prospective, monocentre pilot study of intrahepatic Mitomycin C infusion after radioembolization with Y-90 in chemo refractory liver dominant metastatic breast cancer patients
B.M. Aarts¹, E.G. Klompenhouwer¹, R.C. Dresen², C. Deroose², A. Laenen², R.G.H. Beets-Tan¹, P. Neven², H. Wildiers², G. Maleux²; ¹Amsterdam/NL, ²Leuven/BE
- P-72 Gastric cancer bleeding: treatment with arterial embolization
M.G. Song, T.-S. Seo, S.-J. Park; Seoul/KR
- P-73 The diagnostic role of omental biopsy and guidance in the management of patients with suspected gynaecological malignancy: a single-center experience
O. Sarioglu, H. Sahin, A.E. Capar, U. Belet; Izmir/TR
- P-74 Stent performance in palliative transhepatic treatment of malignant biliary obstruction: covered vs uncovered metallic stents
A. Elkilany¹, M. Al-Warraky², D. Geisel¹, T. Denecke¹; ¹Berlin/DE, ²Menoufia/EG
- P-75 Effectiveness and security of CT-guided percutaneous implantation of radioactive I-125 seeds in locally advanced pancreatic carcinoma
Z. Liao; Chengdu, Sichuan Province/CN
- P-76 Clinical efficacy and safety of transarterial chemotherapy in the treatment for recurrent or persistent ovarian cancer
Y.S. Jeon; Gunpo/KR

- P-79 The right innominate vein as a safe and viable alternative to the right internal jugular vein for ultrasound-guided totally implantable venous access devices in adult patients with cancer
S. Xingwei, J. Yong; Suzhou/CN
- P-80 Efficacy and safety of ultrasound-guided totally implantable venous access ports via the right innominate vein in adult patients with cancer: our single-center experience and protocol
S. Xingwei, J. Yong; Suzhou/CN
- P-81 PSMA-PET/CT and diffusion MRI targeting for cone-beam CT-guided bone biopsies of castration resistant prostate cancer patients
T.R.F. van Steenbergen, M. Smits, T.W.J. Scheenen, J. Nagarajah, I.M. van Oort, M.M. Rovers, N. Mehra, J.J. Fütterer; Nijmegen/NL
- P-82 Hemostatic endovascular embolization of branches of the external carotid artery in patients with the nasopharyngeal tumors
A. Pankov, A. Shelesko, N. Zakaryan, E. Molokhoev, A. Davtyan, V. Kirakosyan; Moscow/RU
- P-84 Experience in five years of retinoblastomas management through intra-arterial chemotherapies in two health institutions of Lima, Peru
P.A. Teran Chávez, M.A. Bedriñana Gomez, D. Quiroz Cerna, C.R. Pascual Morales, G.A. Rojas Salinas, J.C. Tan Kuong, G. Araujo Almeyda, S.C. Alfaro Ita; Lima/PE

Pre-clinical and experimental

- P-85 Embolization of rabbit renal arteries to test feasibility and effects of CT-visible doxorubicin-eluting montmorillonite microparticles
E. Nurili¹, G. Bekaroglu², S. Isci², I. Caymaz², A. Bas², I. Yurdaisik², O. Aras¹; ¹New York, NY/US, ²Istanbul/TR

- P-86 Multifunctional iron oxide nanoparticle-embedded PVP-HEC microparticles as a drug-eluting embolic material
F. Nurili¹, G. Bekaroglu², S. Isci², A. Bas², I. Caymaz², S. Ozkanli², O. Aras¹; ¹New York, NY/US, ²Istanbul/TR
- P-87 Effectiveness and safety of transarterial embolization with Bleomycin-loaded PLA/PLGA microspheres for treatment of vascular malformation using a porcine spleen model
F. Nurili¹, T. Acar², S. Derman², A. Bas², I. Caymaz², S. Ozkanli², H. Cakiroglu³, I. Yurdaisik², O. Aras¹; ¹New York, NY/US, ²Istanbul/TR, ³Adapazari/TR
- P-88 Catheter-directed gastric artery embolisation with octreotide acetate-loaded PLA/PLGA (poly(lactide-co-glycolide) acid) microspheres with slow sustained release properties
F. Nurili¹, T. Acar², S. Derman², A. Bas², I. Caymaz², I. Yurdaisik², H. Cakiroglu³, O. Aras¹; ¹New York, NY/US, ²Istanbul/TR, ³Adapazari/TR
- P-89 The effects of different administration regimens of Apatinib in suppressing the carcinogenesis of VEGF in rats
N. Li, H.Y. Huang; Guangzhou/CN
- P-90 Intratumoral treatment of a pituitary adenocarcinoma in a Jack Russell Terrier using radioactive holmium-166 microspheres
N.C. Morsink¹, N.J.M. Klaassen², B.P. Meij¹, J. Kirpensteijn¹, G.C.M. Grinwis¹, J.W. Hesselink¹, J.F.W. Nijssen², S.A. van Nimwegen¹; ¹Utrecht/NL, ²Nijmegen/NL
- P-91 Effect of irreversible electroporation parameters and the presence of a metal stent on the electric field distribution visualized in a static electric field
A.M. Hogenes¹, C.G. Overduin¹, C.J.H.M. van Laarhoven¹, C.H. Slump², J.J. Fütterer¹, M.W.J. Stommel¹; ¹Nijmegen/NL, ²Enschede/NL

Technical developments

- P-92 Clinical significance and approach of using 3D slicer vessel segmentation and enhancement in Y-90 mapping or TACE pre-treatment planning
Z. Badar¹, S. Nair², K. Ogden¹; ¹Syracuse, NY/US, ²Hamilton, ON/CA
- P-93 Pulmonary nodule CT-guided microcoil localization: tips and tricks
S.R. Alharbi; Riyadh/SA
- P-94 Local thrombolysis for venous port occlusion recovery
M. Cherkashin, N. Berezina, D. Puchkov, E. Napierov, P. Yablonsky; St. Petersburg/RU
- P-95 Picc-port: a better quality of life
F. Incandela, I. Di Gesu, C. Genova, D.G. Castiglione, M. Midiri, T.V. Bartolotta; Palermo/IT
- P-96 A planning software (pre-alpha-stage) for automated calculation/visualization of optimized overlapping ablation zones (optOAZs) for percutaneous thermal ablation (TA) of large (>40mm) renal tumors
C.M. Sommer¹, J. Roeser², F. Pan¹, B. Schmidberger², T.D. Do¹, B.J. Mittmann², P.L. Pereira³, G.M. Richter⁴, H.U. Kauczor¹, A. Franz²; ¹Heidelberg/DE, ²Ulm/DE, ³Heilbronn/DE, ⁴Stuttgart/DE
- P-97 Effectiveness of automated tumor-feeder detection software (ATDS) in super-selective transarterial embolization (TAE)
T. Kubo, Y. Arai, M. Sone, S. Sugawara, T. Magara; Tokyo/JP

- P-98 Technical success and safety profile of balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol Epirubicin-loaded drug-eluting microsphere
P. Lucatelli, G. de Rubeis, L. Ginanni Corradini, B. Rocco, A. Cannavale, P. Nardis, M. Corona, M. Bezzi; Rome/IT
- P-99 Technical efficacy of balloon microcatheter assisted drug-eluting beads trans-arterial chemoembolization for treatment of hepatocellular carcinoma: our preliminary experience
E. Yong, S.N. Babawale, A. Jhamb; Melbourne, VIC/AU
- P-100 Pre-operative marking guided by image: how I do it
R.N. Zangiacomo, D.T. Setuguti, M.R. Liberato, P.C.C. Viana, D.S. Oliveira, L.T.B. Siqueira, M.R. Menezes; São Paulo/BR
- P-101 IR techniques for ischaemic biliary strictures
C.L. Bent, J. Phillips, A. Shawyer; Bournemouth/UK
- P-102 The value of a metal artefact reduction algorithm for monitoring and assessing ablation zones during cone-beam CT-guided pulmonary microwave ablation: a quantitative and qualitative analysis
M. Ozturk, S. Shafer, E. Meram, C. Brace, P. Laeseke; Madison, WI/US



ECIO 2019

European Conference
on Interventional Oncology

April 8-11, 2019

Amsterdam, Netherlands



**LEADERS IN ONCOLOGIC
INTERVENTIONS**

CORPORATE ACTIVITIES & EXHIBITION

Satellite Symposia

Learning Centres

Hands-on Device Training Sponsors

Safe Sedation Training Sponsors

Technical Exhibition

Societies



Cardiovascular and Interventional Radiological Society of Europe



Visit us
at booth
#12

Siemens Healthineers Satellite Symposium

Transforming care delivery through
novel concepts in single- and multi-
modality solutions

siemens-healthineers.com/artis-icone



Monday, April 8, 2019
13:00 – 13:45; Main Auditorium

**Mobile CT intervention suite – clinical application
and radiation dose**

Matthias May, MD
Department of Radiology,
Erlangen University Hospital, Germany

**First results in liver procedures using the new nexaris
Angio-CT**

Élia Coimbra, MD
Interventional Radiology Unit
Hospital Curry Cabral, Lisbon, Portugal

We are looking forward to welcoming you at ECIO 2019.

SIEMENS
Healthineers

Satellite Symposia

Monday, April 8

13:00-13:45, Main Auditorium

Siemens

SY 301 Transforming care delivery through novel concepts in single- and multi-modality solutions

- 301.1 Mobile CT intervention suite – clinical application and radiation dose
M. May (Erlangen/DE)
- 301.2 First results in liver procedures using the new nexaris Angio-CT
É. Coimbra (Lisbon/PT)

BTG AT ECIO 2019



MONDAY, APRIL 8

13:45-14:30 | MAIN AUDITORIUM

SYMPOSIUM:

Bringing Curative Intent Strategies with TheraSphere™ to Europe

Chair: Professor Dr Daniel Seehofer University of Leipzig, Germany

Why I Believe in Curative Intent Strategies with TheraSphere.™ What are the Challenges in Europe?

Professor Dr Daniel Seehofer University of Leipzig, Germany

Moving from Palliation to Curative Intent

Professor Boris Guin St-Eloi University Hospital, Montpellier, France

Building a Bridge for Stronger Partnerships

Dr Michaël Vouche Hôpital Erasme, Université Libre de Bruxelles, Belgium

Viewing SIRT from a New Perspective

Professor Dr Arndt Vogel Medizinische Hochschule, Hannover, Germany

Panel Discussion & Q&A

WEDNESDAY, APRIL 10

10:30-12:00 | HDT Session TA-HDT 5

HANDS-ON WORKSHOP:

Cryoablation and Laser Ablation

Coordinators:

F.M. Gómez Barcelona, Spain; A.H. Mahnken Marburg, Germany

Places are limited to 25 people, allocated on a 'first come, first served' basis

TheraSphere™ is manufactured by Biocompatibles UK Ltd. TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd. BTG and the BTG roundel logo are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks in the US, EU and certain other territories. Biocompatibles UK Ltd is a BTG International group company. © 2019 BTG International Ltd. All rights reserved. CE-THS-1900025. Date of preparation March 2019.

Monday, April 8

13:45-14:30, Main Auditorium

BTG

SY 302 Bringing curative intent strategies with Therasphere™ to Europe

Moderator: D. Seehofer (Leipzig/DE)

- 302.1 Why I believe in curative intent strategies with TheraSphere™. What are the challenges in Europe?
D. Seehofer (Leipzig/DE)
- 302.2 Moving from palliation to curative
B. Guiu (Montpellier/FR)
- 302.3 Building a bridge for stronger partnerships
M. Vouche (Brussels/BE)
- 302.4 Viewing SIRT from a new perspective
A. Vogel (Hanover/DE)

Panel discussion and Q&A

18:30-19:15, Auditorium II

Boston Scientific

SY 601 Patient outcomes in oncology and the role of medical device companies

*Moderators: T. de Baère (Villejuif/FR),
R. Sharma (London/UK)*

- 601.1 How can companies positively impact patient care?
D. Arnold (Hamburg/DE)
- 601.2 Support of the healthcare ecosystem with device company collaboration
A. Gangi (Strasbourg/FR)

VISUALIZE SIRT SUCCESS FROM THE START WITH QUIREMSCOUT™

THE FIRST AND ONLY CE-MARKED
PRODUCT FOR SIRT WORK-UP



from ACCESS
to CLOSURE
INTERVENTIONAL
ONCOLOGY



TERUMO
INTERVENTIONAL
SYSTEMS

www.terumo-europe.com

Not all products are available for sale in all countries. This information is provided only in respect to markets where these products are approved or cleared. Not all products are cleared or approved in the U.S.A. by the Food and Drug Administration. Please contact your Terumo local sales representative for more information.

Tuesday, April 9

13:00-13:45, Main Auditorium



Terumo

SY 1001 SIRT is back – welcome to QuiremScout

*Moderators: D. Arnold (Hamburg/DE),
M.G.E.H. Lam (Utrecht/NL)*

- 1001.1 Introduction and objectives
D. Arnold (Hamburg/DE)
- 1001.2 Treating mNET with Holmium SIRT – new hope
for patients
A.J.A.T. Braat (Utrecht/NL)
- 1001.3 Interactive tumour board discussion
*I. Bargellini (Pisa/IT), A.J.A.T. Braat (Utrecht/NL),
C. Chiesa (Milan/IT), R.-T. Hoffmann (Dresden/DE)*

Questions and answers

VECTORIO®

cTACE Mixing & Injection System

Vectorio® efficacy & safety for improved cTACE mixing & delivery



UNBREAKABLE | USER-FRIENDLY | SHARP

Guerbet | ■■■

LIPIODOL® ULTRA-FLUID. Composition: Ethyl esters of iodized fatty acids of poppy seed oil 10 mL, corresponding to an iodine content of 480 mg/mL. **Indications (**):** In diagnostic radiology - Hysterosalpingography - Ascending urethrography - Lymphography - Sialography - Fistulography and exploration of abscesses - Exploration of frontal sinuses - Pre and post-operative cholangiography. In interventional radiology - Visualization and localization (by selective intra-arterial use during CT) of liver lesions in adults with known or suspected hepatocellular carcinoma - Visualization, localization and vascularisation during Trans-Arterial Chemo-Embolisation (TACE) of hepatocellular carcinoma at intermediate stage, in adults - Selective embolization in combination with Histoacryl glue (particularly for arteriovenous malformation or aneurysms) - Selective injections of LIPIODOL ULTRA-FLUID into the hepatic artery for diagnostic purposes where a spiral CT scan is not practical. In endocrinology - Prevention of severe cases of iodine deficiency. **Posology and method of administration (*):** have to be adapted according to the type of examination, the territories explored, the age and weight of the patient. The volume to be administered depends on the particular requirements of the technique and the size of the patient. **Contraindications:** Hypersensitivity to LIPIODOL ULTRA-FLUID - Confirmed hyperthyroidism - Patients with traumatic injuries, recent haemorrhage or bleeding - Hysterosalpingography during pregnancy or acute pelvic inflammation - Bronchography. In interventional radiology (Trans-Arterial Chemo-Embolisation), Administration in liver areas with dilated bile ducts unless drainage has been performed. **Special warnings and special precautions for use (*):** There is a risk of hypersensitivity regardless of the dose administered. Lymphography: Pulmonary embolism may occur immediately or after few hours to days from inadvertent systemic vascular injection or intravasation of LIPIODOL ULTRA-FLUID. Perform radiological monitoring during LIPIODOL ULTRA-FLUID injection and avoid use in patients with severely impaired lung function, cardiorespiratory failure or right-sided cardiac overload. **Hypersensitivity:** all iodinated contrast agents can lead to minor or major hypersensitivity reactions, which can be life-threatening. These hypersensitivity reactions are of an allergic nature (known as anaphylactic reactions if they are serious) or a non-allergic nature. They can be immediate (occurring within 60 min) or delayed (not occurring until up to 7 days later). Anaphylactic reactions are immediate and can be fatal. They are dose-independent, can occur right from the first administration of the product, and are often unpredictable: avoid use in patients with a history of sensitivity to other iodinated contrast agents, bronchial asthma or allergic disorders because of an increased risk of a hypersensitivity reaction to LIPIODOL ULTRA-FLUID. **Thyroid:** can cause hyperthyroidism in predisposed patients. Lymphography saturates the thyroid with iodine for several months and thyroid exploration should be performed before radiological examination. **Chemo-Embolisation:** Trans-Arterial Chemo-Embolisation is not recommended in patients with decompensated liver cirrhosis (Child-Pugh aB), advanced liver dysfunction, macroscopic invasion and/or extra-hepatic spread of the tumor. Renal insufficiency must be prevented by correct rehydration before and after the procedure. Oesophageal varices must be carefully monitored. Hepatic intra-arterial treatment can progressively cause an irreversible liver insufficiency in patients with serious liver malfunction and/or undergoing close multiple sessions. The risk of superinfection in the treated area is normally prevented by administration of antibiotics. **Embolization with glue:** An early polymerisation reaction may exceptionally occur between LIPIODOL ULTRA-FLUID and certain surgical glues, or even certain batches of glue. Before using new batches of LIPIODOL ULTRA-FLUID or surgical glue, the compatibility of LIPIODOL ULTRA-FLUID and the glue must be tested in vitro. **Interaction with other medicinal products and other forms of interaction (*):** Metformin, Beta blockers, vasoactive substances, angiotensin-converting enzyme inhibitors, angiotensin-receptor antagonists, Diuretics, Interleukin II. **Fertility, pregnancy and lactation (*):** LIPIODOL ULTRA-FLUID must only be used in pregnant women if absolutely necessary and under strict medical supervision. Breastfeeding should be discontinued if LIPIODOL ULTRA-FLUID must be used. **Effects on ability to drive and use machines:** The effects on ability to drive and to use machines have not been investigated. **Undesirable effects (*):** Most adverse effects are dose-related and dosage should therefore be kept as low as possible. Hypersensitivity, anaphylactic reaction, anaphylactoid reaction, vomiting, diarrhoea, nausea, fever, pain, dyspnoea, cough, hypothyroidism, hyperthyroidism, thyroiditis, pulmonary embolism, cerebral embolism, retinal vein thrombosis, lymphoedema aggravation, hepatic vein thrombosis, granuloma. **Overdose (*):** The total dose of LIPIODOL ULTRA-FLUID administered must not exceed 20 mL. **Pharmacodynamic properties (*):** Pharmacotherapeutic group: X-ray contrast media, iodinated; ATC code: V08A D01. Water-insoluble iodinated contrast medium. **Presentation (*):** 10 mL glass ampoule. **Marketing authorization holder (*):** Guerbet - BP 57400 - F-95943 Roissy CdG cedex - FRANCE. Information: tel: 33 (0) 1 45 91 50 00. **Revision:** April 24th, 2018.

(*) For complete information please refer to the local Summary of Product Characteristics (SPC).

(**) Indications, volumes and presentations may differ from country to country.

Reporting of suspected adverse reactions is important as it helps to continuously assess the benefit-risk balance. Therefore, Guerbet encourages you to report any adverse reactions to your health authorities or to our local Guerbet representative.

VECTORIO® is a medical device of Class Is (CE 0459) intended to be used by healthcare professionals only. Manufacturer: Medex, a Guerbet Group company. **Intended use:** Lipiodol® Resistant Mixing & Injection System for conventional Trans-Arterial Chemo-Embolization (cTACE).

For complete information please refer to country's local Package Information Leaflet & Vectorio® Instruction For Use (IFU).

Countries in which cTACE indication is registered: Austria, Argentina, Belgium, Brazil, Cambodia, Czech Republic, France, Japan, Hong Kong, Hungary, Ireland, India, Iran, Mexico, Mongolia, New Zealand, Peru, Portugal, Philippines, South Korea, Turkey, The Netherlands, Thailand, Taiwan, Tunisia, Vietnam.

For a copy of the SPC/ IFU, please contact a member of Guerbet.

13:45-14:30, Main Auditorium

Guerbet

**SY 1002 HCC treatment, a broader spectrum
of opportunities for patients**

Moderator: J.-P. Pelage (Caen/FR)

1002.1 Introduction

J.-P. Pelage (Caen/FR)

1002.2 Updated clinical data in cTACE, towards increasing
survival

J. Karani (London/UK)

1002.3 cTACE & RFA, an effective therapeutic approach to
treat specific patients

A. Denys (Lausanne/CH)

1002.4 Non-target embolisation: an ignored problem?

J.-P. Pelage (Caen/FR)

Questions and conclusion

Visit CLS
booth #11



You are Invited!

Satellite Symposium in Meeting Room I, Tuesday at 18.30
Hands On Device Training, Wednesday at 10.30


TRANBERG®|Thermal Therapy System

When precision really matters

Main features and benefits

- MR, US or CT image guidance
- Tissue temperature controlled power output
- Laser ablation in focal therapies
- Immune Stimulating Interstitial Laser Thermotherapy (imILT®)

With soon-to-come software for MR thermometry and tissue damage during delivery of thermotherapy



www.clinicallaser.com



Tuesday, April 9

18:30-19:45, Meeting Room I (G 110)

CLS

SY 1301 Modification of laser ablation creates strong immune stimulatory effects

Moderator: A.H. Mahnken (Marburg/DE)

1301.1 Introduction

A.H. Mahnken (Marburg/DE)

1301.2 Abscopal effect – a case report

B. Gonçalves (Porto/PT)

1301.3 Immune stimulating interstitial laser
thermotherapy (imILT) – the scientific background

K.-G. Tranberg (Lund/SE)

1301.4 imILT – in immunological context

G. Hedlund (Lund/SE)

1301.5 Laser ablation on Locally Advanced Pancreatic
Cancer (LAPC) – clinical results, surgeon's view

O. Turrini (Marseille/FR)

1301.6 imILT – future aspects

B. Gonçalves (Porto/PT)

Discussion



SATELLITE LUNCH SYMPOSIUM

**Redefine Interventions with a
One Room Angio-CT solution**

Wednesday, April 10, 2019 | Room: Main Auditorium, 13.45 - 14.30

Chairman

Prof. B. Guiu

University Hospital Montpellier, France

LECTURE 1

*Revisited prostate artery
embolization using
Infinix-i 4D CT*

Speaker:

Dr. G. Amouyal

Saint-Louis University Hospital,
Paris, France

LECTURE 2

*Alphenix 4D CT: A bright future
for multi-modality interventions*

Speaker:

Prof. T. de Baere

Gustave Roussy, Villejuif, France

Wednesday, April 10

13:00-13:45, Main Auditorium

Sirtex

SY 1701 Maximising the impact of SIRT with SIR-Spheres Y-90 resin microspheres

Moderator: T.K. Helmberger (Munich/DE)

- 1701.1 Tips and tricks to handle tricky situations in clinical practice
M.C. Burgmans (Leiden/NL)
- 1701.2 Selecting the right treatment for the patient
I. Bargellini (Pisa/IT)

Panel discussion

13:45-14:30, Main Auditorium

Canon

SY 1702 Redefine interventions with a one-room angio-CT solution

Moderator: B. Guiu (Montpellier/FR)

- 1702.1 Revisited prostate artery embolisation using Infinix 4DCT
G. Amouyal (Paris/FR)
- 1702.2 Alphenix 4DCT: a bright future for multi-modality interventions
T. de Baère (Villejuif/FR)



**Boston
Scientific**

Advancing science for life™

SIZED FOR SUCCESS

Embozene TANDEM™ Microspheres
are sized for **DEB TACE** success:

- Deep targeted embolisation
- Predictable homogeneous tumor coverage
- Improved drug exposure
- Consistent and reliable preparation

All cited trademarks are the property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. Material not intended for use in France.

PI-535906-AA MAR 2018 © 2018 Boston Scientific Corporation or its affiliates. All rights reserved.

Learning Centres

The Learning Centres at ECIO 2019 will provide an excellent opportunity for all congress delegates to test the latest interventional devices, gain hands-on experience with new equipment and talk to industry representatives.

Please note that CIRSE is not responsible for the information provided at the Learning Centres.

Boston Scientific

For information about our Learning Centre activities please visit our booth #22.

Terumo

Terumo Educational Services: For information about our Learning Centre activities please visit booth #13.

Guerbet**Innovation Lab programme – April 8-11, 2019****Learn more on cTACE mixture standardisation using Vectorio®****Monday through Thursday**

09:30-12:30

13:30-17:30 (except April 11)

By Philippe Havard and Amy Wei
Innovation Lab Vectorio®**Discover Sequire® Control Reflux microcatheter –
How to minimise non-target embolisation****Monday through Thursday**

09:30-12:30

13:30-17:30 (except April 11)

By Frederique Delplanque and Eam-Maly Nam
Innovation Lab Sequire®

Medtronic**Monday, April 8**

10:00-10:45

Microwave ablation liver

M. Meijerink (Amsterdam/NL)

11:00-11:45

Microwave ablation lung

H.H. Torp Madsen (Aarhus/DK)

14:30-15:30

Optimising bone metastasis local tumour control

R.L. Cazzato (Strasbourg/FR)

Tuesday, April 9

10:00-10:45

Microwave ablation kidney

K.I. Ringe (Hannover/DE)

11:00-11:45

Microwave ablation liver laparoscopic

F. De Cobelli (Milan/IT)

Wednesday, April 10

10:00-10:45

Microwave ablation kidney

K.I. Ringe (Hannover/DE)

11:00-11:45

Microwave ablation liver


M. Meijerink (Amsterdam/NL)

PREDICTABILITY FOR YOU. OPTIONS FOR YOUR PATIENTS.

Emprint™ Ablation System

LEARNING
CENTER &
ROUND TABLE
DISCUSSIONS
ECIO 2019

April 8-11, 2019



Emprint™ Ablation System

Learning center
Microwave Ablation:
Liver, Lung, Kidney,
Liver laparoscopic

Round table discussions
A tumor board discussion



To book your place in one of the Learning Center sessions or in one of the Round Table Discussions **Scan QR Code**, or visit:
www.eventbrite.co.uk/e/ecio-2019-learning-center-and-round-table-discussions-by-medtronic-tickets-55689960170

© 2019 Medtronic. All rights reserved.
19-wau-ecio-2019-pocket-guide-2959380

Medtronic
Further. Together

Hands-on Training Sponsors

Hands-on Training sessions are kindly supported by the following industry partners:

- AngioDynamics
- Bracco
- BTG
- Canyon
- CAscination
- Clinical Laserthermia Systems (CLS)
- ECO Medical
- Endocare
- HS Hospital Service S.p.A.
- IceCure Medical
- Merit Medical
- NeuWave Medical
- Olympus Surgical Technologies Europe
- Siemens
- Surgnova
- Terumo


The Safe Sedation Training sessions are kindly supported by Medtronic and organised in cooperation with the AQAI Simulation Center.

For detailed information on Hands-on Device Training and the Safe Sedation Training, please refer to pages 14-17.

If you are interested in obtaining product information outside of the Hands-on Training sessions, please visit the respective company booth in the exhibition area.

For further information about the industry partners, please refer to the Technical Exhibitors Guide (pages 84-120).

Diamond Sponsors



DIAMOND



BTG

Booth # **23**

Canon

CANON MEDICAL

Booth # **25**

Guerbet |

Booth # **24**

Medtronic

Further, Together

Booth # **14**

SIRTeX

Booth # **21**

TERUMO
INTERVENTIONAL
SYSTEMS

Booth # **13**

CIRSE

Platinum | Gold | Silver Sponsors



Platinum Sponsors

Boston Scientific	Booth # 22
Siemens	Booth # 12

Gold Sponsors

Clinical Laserthermia Systems	Booth # 11
Merit Medical	Booth # 1
Neuwave	Booth # 26

Silver Sponsors

Canyon	Booth # 10
CAScination	Booth # 2
HS Hospital Service	Booth # 3
IGEA	Booth # 19
Pharmacept	Booth # 4
Philips	Booth # 28
RF Medical Co., LTD.	Booth # 5

Technical Exhibition (Alphabetical List)

Official Name	Booth #
AngioDynamics	20
AprioMed	32
Boston Scientific International	22
Bracco Imaging	15
BTG	23
Canon Medical Systems Europe	25
Canyon Medical	10
CAScination	2
Clinical Laserthermia Systems	11
Cook Medical Europe	18
ECO Microwave	17
Encapson	29
Endocare	16
Guerbet	24
H.S. Hospital Service	3
IceCure Medical	7
IGEA Clinical Biophysics	19
Imactis	31
Interventional News	18b
medac GmbH	34
Medtronic	14
Merit Medical Austria	1
MIM Software	6
NeuWave Medical	26
PharmaCept	4
Philips Medical Systems	28
RF Medical	5
Siemens Healthcare	12
SIO (Society of Interventional Oncology)	18a
Sirtex Medical Europe	21
Soteria Medical	33
STARmed	9
Surgnova Healthcare Technologies	8
Terumo Europe	13
Varian Medical	30

Technical Exhibition (Numerical List)

Official Name	Booth #
Merit Medical Austria	1
CAScination	2
H.S. Hospital Service	3
PharmaCept	4
RF Medical	5
MIM Software	6
IceCure Medical	7
Surgnova Healthcare Technologies	8
STARmed	9
Canyon Medical	10
Clinical Laserthermia Systems	11
Siemens Healthcare	12
Terumo Europe	13
Medtronic	14
Bracco Imaging	15
Endocare	16
ECO Microwave	17
Cook Medical Europe	18
SIO (Society of Interventional Oncology)	18a
Interventional News	18b
IGEA Clinical Biophysics	19
AngioDynamics	20
Sirtex Medical Europe	21
Boston Scientific International	22
BTG	23
Guerbet	24
Canon Medical Systems Europe	25
NeuWave Medical	26
Philips Medical Systems	28
Encapson	29
Varian Medical	30
Imactis	31
AprioMed	32
Soteria Medical	33
medac GmbH	34

Technical Exhibitors Guide

AngioDynamics, Inc.

20

Phone: + 31 207 532 949

Email: customerservice@angiodynamics.comwww.AngioDynamics.com

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. Stop by AngioDynamics booth to find out more about our NanoKnife, Irreversible Electroporation (IRE), Solero Microwave Tissue Ablation (MTA) and BioSentry tract sealant Systems.

AprioMed AB

32

Virdings Allé 28

754 50 Uppsala

Sweden

www.apriomed.com

AprioMed develops, manufactures, markets and sells innovative medical devices and related services within the field of interventional radiology. We aim to deliver, in close collaboration with healthcare practitioners, innovative quality tools to achieve the most favourable solutions for radiologists worldwide.

Boston Scientific International SA



22

Parc d'Affaires Val Saint Quentin –
Bâtiment H
2 Rue René Caudron
78960 Voisins-le-Bretonneux
France
Phone: +33 139 309 700
Email: ReceptionFrance@bsci.com
www.bostonscientific.eu

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.

Bracco Imaging Spa

15

Via Caduti di Marcinelle 13
20134 Milan
Italy
Email: mediarelations.imaging@bracco.com
www.braccoimaging.com

Bracco Imaging S.p.A., part of the Bracco Group, is one of the world's leading companies in the diagnostic imaging business. Headquartered in Milan, Italy, Bracco Imaging develops, manufactures and markets diagnostic imaging agents and solutions that meet medical needs. Bracco Imaging offers a product and solution portfolio for all key diagnostic imaging modalities: X-ray Imaging (including Computed Tomography-CT, Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance Imaging (MRI), Contrast Enhanced Ultrasound (CEUS) and Nuclear Medicine through radioactive tracers. The diagnostic imaging portfolio is completed by several medical devices and advanced administration systems for contrast imaging products in the fields of radiology. The Company operates in over 100 markets worldwide, either directly or indirectly, through subsidiaries, joint ventures, licenses and distribution partnership agreements. To learn more about Bracco Imaging, visit www.braccoimaging.com

BTG

Lakeview, Riverside Way
Watchmoor Park, Camberley
GU15 3YL Surrey
United Kingdom
Phone: +44 127 690 202 0
Email: info@btgplc.com
<https://btgplc.com/en-US/Interventional-Oncology>



DIAMOND

23**BTG**

BTG Interventional Oncology is transforming the way cancer is treated with our wide-ranging solutions of minimally-invasive, highly targeted cancer therapies. We are leaders in developing intelligent, loco-regional treatments that can be personalised to each patient's needs. Our treatments include elegant and innovative new medicines, improved device technology and ground-breaking delivery techniques. Our products are used to treat and provide symptomatic relief for people with cancer and benign tumours. By specifically targeting diseased cells, we can limit the impact on healthy tissue. Our solutions include embolisation beads, drug-eluting beads, radiotherapy treatment that uses yttrium-90 glass microspheres, and cryoablation delivery systems. By partnering with the brightest minds in medicine and technology, we are committed to better serving healthcare professionals and delivering improved healthcare for those who deserve it the most, the patients. Healthcare is evolving and at BTG Interventional Oncology we believe intelligent science is the way forward. To learn more about BTG Interventional Oncology, please visit: btg-io.com and follow us on Twitter @BTGIO.

Canon Medical Systems Europe B.V.

Zilverstraat 1

2718 RP Zoetermeer

The Netherlands

Email: jan.debruijn@eu.medical.canon<https://eu.medical.canon/>

DIAMOND

25**Canon**

CANON MEDICAL

Canon Medical offers a full range of diagnostic medical imaging solutions including CT, X-Ray, Ultrasound and MRI, across the globe. As of December 2016, Canon Medical became a member of the Canon Group. In line with our continued Made For life philosophy, patients are at the heart of everything we do. Our mission is to provide medical professionals with solutions that support their efforts in contributing to the health and wellbeing of patients worldwide. Our goal is to deliver optimum health opportunities for patients through uncompromised performance, comfort and safety features.

At Canon Medical we work hand in hand with our partners – our medical, academic and research community. We build relationships based on transparency, trust and respect. Together as one, we strive to create industry-leading solutions that deliver an enriched quality of life.

Canyon Microwave Ablation

Ablation with Confidence



Precise, Stable, Safe, and more

Add: No.10 Gaoke 3rd Road, National Hi-Tech Zone, Nanjing, China

www.canyonmedical.com.cn

sales@canyonmedical.com.cn

Canyon Medical Inc.

No.10 Gaoke 3rd Road

National Hi-Tech Zone

Nanjing

China

Phone: +86 255 885 0594

Email: sales@canyonmedical.com.cn

www.canyonmedical.com.cn

**10**

Canyon Medical is specialized in Microwave Ablation for over 30 years with more than 100,000 accumulated cases done successfully with our system in China. By innovating with clinical practices hands in hands, we are pioneering to solve clinical challenges in this field. In view of our continuous and prominent contribution, our company was granted with many great honors, like the National Award for Scientific and Technological Invention in 2014. In 2015, Canyon Medical joined the family of Micro-Tech. In virtue of Micro-Tech's international platform and management philosophy, Canyon Medical is advancing towards a greater international stage at a higher level. As a leading brand in China with endless efforts in product design and R&D, we are proud to announce a new generation Microwave ablation device here.

CAS^{CINATION}



CAS-ONE IR

Stereotactic Navigation System
for Tumor Treatment



www.cascination.com

CAScination AG

Steigerhubelstrasse 3

3008 Bern

Switzerland

Phone: +41 315 520 441

Email: info@cascination.comwww.cascination.com**2**

From research to worldwide success – CAScination is dedicated to the development, manufacture and commercialization of innovations in computer-assisted and image-guided interventional radiology and surgery. Our trailblazing navigation systems and surgical robots are designed to improve outcomes for those undergoing surgical or interventional procedures and offer new perspectives to patients worldwide. Our CAS-One planning and navigation system is used to treat patients suffering from soft tissue cancer (e.g., liver cancer). We aim to provide physicians with the tools needed to ensure precise, reproducible and efficient therapy, and give more patients access to minimally invasive and effective treatments, helping them to recover fast and get back to enjoying life. Our CAS-One planning and navigation system is CE marked and FDA cleared, and is used in many hospitals across the world. Our portfolio of products and solutions includes navigation systems for open and minimally invasive cancer treatment as well as an otological planning software OTOPLAN. CAScination is committed to continuously expanding the indications of precision navigation for the benefit of patients worldwide.

Clinical Laserthermia Systems AB

(publ) (CLSB Nasdaq First North)

Medicon Village

Scheelevägen 2

223 81 Lund

Sweden

Phone: +46 461 521 00

Email: info@clinicallaser.sewww.clinicallaser.seCEO: Lars-Erik Eriksson, lee@clinicallaser.se**11**

Clinical Laserthermia Systems (CLS) develops and sells the TRANBERG® Thermal Therapy System for safe, gentle and effective treatment of cancerous tumors. The system is marketed for image-guided laser ablation and for treatment with CLS' proprietary Immuno-stimulating Interstitial Laser Thermo-therapy, imILT®. The TRANBERG® system can be configured for MR or CT/US-guided procedures with monitoring and feedback of tissue temperature for exact therapy and ablation control. It consists of a mobile laser unit, non-cooled laser applicators, external tissue temperature sensors and procedure-specific accessories. In collaboration with Image Guided Therapy, MRI Interventions and Siemens Healthineers, CLS is currently developing a software platform for navigation and temperature control during MR guided treatment with the TRANBERG system. The launch of the first product is scheduled to second half of 2019 and will provide clinicians a complete package for an optimized workflow during treatment. Clinical studies regarding imILT treatment of breast cancer and pancreatic cancer have been carried out 2016-2018 under the EU Horizon2020-program. The treatment was well-tolerated by the patients, and usability and safety of the equipment was excellent. A clinical study of image-guided ablation treatment of prostate cancer is currently taking place in Toronto, Canada. Read more at www.clinicallaser.com

Cook Medical
18

EMEA Support Centre
 O'Halloran Road
 National Technology Park
 Limerick
 Ireland
 Phone: +353 613 344 40
 Fax: +353 613 344 41
 Email: EMEAenquiry@CookMedical.com
www.cookmedical.eu

Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials, and cellular therapies to help the world's healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees, and our communities. For more information, visit www.cookmedical.eu.

Eco Microwave
17

10th Floor, Block 2, Binjiang Plaza
 No.305, Jiangdong North Road
 210036 Nanjing
 China
 Phone: +86 258 626 281 7
 Fax: +86 258 626 277 7
www.ecomicrowave.com

Since 2000, ECO Medical has been a medical device manufacturer specialized in microwave ablation, high frequency, and physical therapy products. The objective is to provide safer and more accurate minimally invasive treatment for patients. Please visit www.ecomicrowave.com for more information.

Encapson**29**

Institutenweg 25A
7521PA Enschede
The Netherlands
Phone +31 247 110 330
Email: info@encapson.com
www.encapson.com

Encapson is a medical technology company with the mission to improve patient care through innovative echogenic visibility solutions for medical devices. Sono-Coat™ is a best in class coating-based visibility system that significantly improves the ultrasound visibility of medical devices in the body leading to better patient outcomes. The unmatched ultrasound visibility of Sono-Coat™ enables doctors carrying out difficult minimally invasive procedures. Sono-Coat™ is a game-changing technology in situations “when precision counts”. It enables precise targeting of objects in deeper tissue structures (e.g. liver and kidney biopsies) and supports the physician in performing accurate, safe and error-free ultrasound-guided minimally invasive procedures.

Endocare, Inc.**16**

9825 Spectrum Drive, Bldg. 2
TX 78717 Austin
United States
Email: david.russell@endocare.com
www.endocare.com

Endocare, Inc. is a medical device company focused on the development of minimally invasive tumor ablation technologies including percutaneous cryoablation and microwave ablation. With over 15 years of clinical experience in percutaneous ablation of kidney, lung, painful metastases to bone, nerve pain, and other tissues, we remain committed to innovative technology that improves and extends patients' lives.

Guerbet

BP57400

95943 Roissy CDG Cedex

France

Email: direction.communication@guerbet-group.comwww.guerbet.com

DIAMOND

24**Guerbet** | The logo icon for Guerbet, consisting of a 3x3 grid of squares. The top-right square is orange, and the others are blue.

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices, and services for diagnostic and interventional imaging to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed across its four centres in France, Israel, and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com

HS AMICA

Re-Thinking Ablation

1 System 2 Technologies

MWA & RFA

- Freedom of Choice
- High Performance
- Optimized Control
- Enhanced Safety
- Extended Interactivity
- Dedicated Software



hshospitalservice.com

H.S. Hospital Service SpA

Via Zosimo 13

00178 Roma

Italy

Email: f.varani@hshospitalservice.com

Phone: +39 (0) 692 019 61

Fax: +39 (0) 692 755 19

www.hshospitalservice.com**3**

HS Hospital Service Spa is a leading player in the international interventional oncology market, from RF and MW tumor ablation systems to soft tissue and bone marrow biopsy needles, catheters, drug infusion devices and all sorts of products for surgery, interventional radiology and critical care. In the field of health technologies, success may only be achieved through excellence. We are committed to delivering excellence all the way from product design and manufacturing to post-sale customer care. We transfer know how and expertise from industrial research to the clinical field and back. Every day we work side by side with physicians and interact with all the stakeholders in interventional oncology for better understanding and fulfilling their needs and requirements, so to deliver to the market top level devices, with optimum performance, minimum invasiveness and unmatched usability. Let us show you our new products and projects and let us share with you information, ideas, plans and strategies for the future! Please come and visit us at booth number 3!

CLINIPORATOR™

LEADING CLINICAL ELECTROPORATION



**The most advanced
electroporation technology**

for treatment of tumour nodules located to the skin,
subcutaneous tissue, parenchyma and bone.

IGEA®
CLINICAL BIOPHYSICS

www.igeamedical.com

IGEA S.p.A.

Via Parmenide, 10/A

41012 Carpi (MO)

Italy

Phone: +39 059 699 600

Fax: +39 059 695 778

www.igeamedical.com

**19**

IGEA works to improve patient's Quality of Life developing and producing, from own original projects, innovative, effective and safe therapeutic systems for clinical practice. IGEA develops biophysical treatments in two main areas: Orthopedics: to improve bone healing and joint preservation. Oncology: to treat cancer. The Cliniporator® and the Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumor nodules located to the skin, subcutaneous tissue, parenchyma and bone.

IceCure Medical Ltd.**7**

7 Haeshel St.

3088900 Caesarea

Israel

Tlalit Bussi Tel Tzure- VP Marketing

Email: tlalitb@icecure-medical.com

Mobile: +972 545 650 737

Phone: +972 462 303 33

Fax: +972 462 302 22

www.icecure-medical.com<https://www.linkedin.com/company/icecure-medical/><https://twitter.com/icecuremedical>

IceCure Medical – Innovating Cryotherapy Solutions. Setting new standards in minimally-invasive tumor therapy IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for women's health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, IceCure's core technology is based on cryoablation, using freezing temperature (liquid nitrogen) to effectively destroy tumors safely, quickly, and painlessly, without the need for surgery. Proprietary liquid nitrogen technology for maximum efficiency Based on liquid nitrogen, IceCure's proprietary third-generation technology generates lower tissue temperatures and a faster cooling rate than other methods, to enable a larger ice-ball tumor killing area for maximum efficacy. Enabling in-office treatment options – Commercially available in the U.S.A., Europe, Hong-Kong, Thailand, Singapore and South-Central America, its flagship system, ProSense™, uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The easy-to-use ProSense™ cryoablation procedure enables full physician control and can be performed in less than 30 minutes in the comfort of a doctor's office. As a proven solution for the treatment of fibroadenomas (benign breast tumors), the ProSense™ system is also indicated for use in the fields of general surgery, oncology, gynecology and urology.

Imactis
31

20 rue du Tour de l'Eau
38400 Saint-Martin-d'Hères
France
Email: sales@imactis.com
Phone: + 33 458 005 580
Fax: + 33 458 005 583
www.imactis.com

Imactis is specialized in computer assisted interventional radiology. Imactis develops and markets innovative solutions to assist interventional radiologists during minimally invasive needle procedures (biopsies, tumor ablations, vertebroplasties, infiltrations, drainages...). The objective is to increase accuracy and safety, facilitate complex procedures, reduce the length of procedures, decrease the number of controls and improve patient treatment.

Interventional News
18b

BIBA Medical Ltd
526 Fulham Road
SW6 5NR London
United Kingdom
Email: shilpa@bibamedical.com
www.interventionalnews.com

Interventional News is a specialized, quarterly newspaper, which goes out to over 12,000 subscribers in Europe and North America. Published by BIBA Medical, it is an editorially independent news brand, steered by internationally renowned editors-in-chief, Professor Andy Adam and Brian Stainken, MD. Interventional News contains the latest news, opinion from thought leaders in interventional radiology, summaries of cutting-edge research, expert analysis, conference coverage, information and updates on the latest products and the medical device industry.

medac GmbH**34**

Theaterstrasse 6

22880 Wedel

Germany

Email: contact@medac.de

Phone: +49 410 380 060

Fax: +49 410 380 061 00

www.medac.de

medac Gesellschaft für klinische Spezialpräparate mbH – medac is a privately held, global pharmaceutical company with a growing pharmaceutical and diagnostics business. Established 1970 in Northern Germany, medac is specialised in the treatment of oncological, haematological, urological and autoimmune diseases as well as in the development of diagnostic devices. Besides an already established product portfolio, medac is dedicated to the refining of existing and the development of new therapeutic products providing patients with leading-edge individualised treatments. Further information about the company and its products can be found online at www.medac.de

Medtronic

Victor-von-Bruns-Strasse 19
8212 Neuhausen am Rheinfall
Switzerland
Contact: Francesca Zucchetti
Mobile: +39 335 780 722 2
Email: francesca.zucchetti@medtronic.com
www.medtronic.com



DIAMOND

14

Medtronic
Further. Together

Making healthcare better is our priority, and we believe medical technology can play an even greater role in improving people's lives. With challenges facing families and healthcare systems – such as rising costs, aging populations, and the burden of chronic disease – we are using the power of technology to take healthcare Further, Together. Innovation and collaboration are central to who we are. Since the late 1940s, we have been working with others to alleviate pain, restore health, and extend life. Today, we are a medical technology leader, employing more than 84,000 people worldwide, and offering therapies and solutions that enable greater efficiency, access, and value – for healthcare systems, providers, and the people they serve. Learn more at Medtronic.com.

FIND AND DESTROY*

* Spinal Tumours



HUNTINGTON™ BONE BIOPSY SYSTEM

Our bone biopsy systems including the Huntington™ and Madison™ offer physicians the luxury of choice, whilst optimising diagnostic yield. Unique engineering allows for traversing dense bone with tactile drilling, and guided access options can provide added confidence and procedural efficiency.



STAR™ TUMOUR ABLATION SYSTEM

Confidently treat metastatic spinal tumours with the STAR Tumour Ablation System using targeted radiofrequency ablation (t-RFA).

Merit Medical

Amerikalaan 42
6199AE Maastricht
The Netherlands
Phone +31 433 588 222
www.merit.com

**1**

Founded in 1987, Merit Medical Systems, Inc. is a worldwide company engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology, embolic therapy and endoscopy. We have built a comprehensive embolotherapy suite of products, including tools to deliver your embolics right to the target. HepaSphere™ Microspheres deliver excellent objective response rates for embolisation of hepatocellular carcinoma and metastases to the liver; SwiftNINJA® is a straight tip catheter that articulates up to 180 degrees in opposing directions to rapidly select the most challenging vascular ostium; True Form™ is a 0.014" reshapable guide wire that can be shaped multiple times and maintain its shape during procedures. Our focus on interventional spine continues to increase, with tools to treat metastatic spinal tumors as well as vertebral compression fractures. We also offer devices and kits for soft tissue, bone and muscle biopsy, for everyday procedures and more challenging needs. These coaxial systems feature unique hard bone access and guide wire technologies, and all include a clockwise-cutting trephine bone biopsy needle to optimise diagnostic yield. Our team will be delighted to see you at our booth and present our product portfolio.

NEUWAVE™ Microwave Ablation System

Build your ablation program with the system that has it all

COME AND SEE US AT ECIO 2019 / STAND 26

- **PR Probe** with distal energy control to help protect non-target tissue
- **Multi-probe synchrony** for large ablations with 2 or 3 probes
- **CO₂ cooling** for 17 gauge probes and Tissu-Loc™ to help reduce probe migration
- **Ablation Confirmation** software to evaluate the technical success of procedures



ETHICON

PART OF THE **Johnson & Johnson** FAMILY OF COMPANIES

DISCLAIMER: The NEUWAVE™ Microwave Ablation System is cleared for the ablation coagulation of soft tissue in percutaneous, open surgery and in conjunction with laparoscopic surgical settings. The NEUWAVE™ Microwave Ablation System is not cleared for treatment of any specific disease or condition. The NEUWAVE™ Microwave Ablation System is not indicated for use in cardiac procedures. The system is designed for facility use and should only be used under the orders of a clinician. Clinicians should exercise their independent medical judgment in use of the system.

MIM Software Inc.**6**

25800 Science Park Dr – Ste 180
OH 44122 Cleveland
United States
www.mimsoftware.com

MIM Software Inc. provides practical imaging solutions in the fields of radiology, nuclear medicine, radiation oncology, urology, neuroimaging, and cardiac imaging. MIM SurePlan LiverY90 provides timesaving tools for liver and tumor segmentation, deformable registration, and post-treatment dosimetry using Y90-PET and Bremsstrahlung SPECT. MIM SurePlan MRT provides timesaving tools for organ and tumor segmentation, deformable registration, and voxel-based dosimetry for molecular radiotherapy.

NeuWave Medical, Inc.**26**

Johnson & Johnson Medical Devices
Companies/Neuwave
3529 Anderson St
WI 53704 Madison
United States
www.neuwave.com

About the Johnson & Johnson Medical Devices Companies:
The Johnson & Johnson Medical Devices Companies have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services. About Neuwave Ethicon: The NEUWAVE™ Microwave Ablation System, now a part of the Ethicon™ portfolio of products, is the first intelligent ablation system and the only system that has it all. The versatile probe portfolio with multi-probe synchronized energy delivery allows physicians to tailor ablations with 1, 2 or 3 probes. In addition, the 17-gauge NEUWAVE™ PR probe is the only probe available with distal energy control to help protect non-target tissue. The unique computer-controlled system now includes Ablation Confirmation™ software, offering the only integrated in-procedure confirmation to help confirm probe placement and evaluate the technical success of your procedure. Build your ablation program with the first intelligent ablation system and the only system that has it all.

ESIR 2019 Courses

European School of Interventional Radiology

Clinical Procedure Training

ESIR stays abreast of new developments in IR with this hand-picked selection of hot topics and access to state-of-the-art technology. Taught by distinguished faculty members, these specially designed sessions are aimed at experienced interventional radiologists who are already familiar with the topic's theoretical aspects and the relevant literature. Alongside "tips and tricks", this year's programme will put an emphasis on modern procedural training and practical exercises, with live or recorded cases being used where appropriate.



DEB & cTACE in Primary and Secondary Liver Cancer Munich (DE), June 6-7, 2019

Local Host: T.F. Jakobs

Hospital Barmherzige Brüder Munich



Reliability in Percutaneous Tumour Ablation Innsbruck (AT), Dec. 12-13, 2019

Local Hosts: R. Bale & W. Jaschke

LKH – Universitätskliniken Innsbruck

For more information, please visit
www.cirse.org/esir

PharmaCept GmbH

Bessemerstrasse 82

12103 Berlin

Germany

Phone: +49 30 756 598 50

Fax: +49 30 756 598 511

Email: info@pharmacept.comwww.pharmacept.com**4**

PharmaCept stands for the successful development of niche products for various cancer indications with a special focus on research in Interventional Oncology. The main pillar of our company's development is the embolization and chemoembolization therapy. Based on the degradable starch material new spheres for UFE and BPH-embolization are in the process of development. With our product EmboCept® S, the only short-term embolic agent, malignant tumor growth can be considerably reduced. New clinical studies will continue to explore scientifically already known advantages of degradable starch microspheres and unlimited combination with drugs, e.g. our new Cisplatin powder PlatiCept®. Cisplatin powder is the second most commonly used chemotherapeutic agent for primary liver cancer. It can be used as an alternative drug to doxorubicin, within a combination or after a tumor progression under anthracyclines. Our experimental data show a significantly increased accumulation of platin products in tumor tissue when it is used in combination with starch microspheres (EmboCept® S).



PHILIPS

ECIO 2019

PHILIPS

Philips Azurion with FlexArm

The advanced
suite that works
around you

**Visit us at
booth 28**

**Discover unlimited flexibility
for complex oncology cases**

innovation ✨ you

Philips

Royal Philips
Amstelplein 2, Breitner Center
P.O. Box 77900
1070 MX Amsterdam
The Netherlands
Phone +31 20 59 77777
www.philips.com
www.philips.com/igt

**28**

Philips is a leading health technology company focused on improving people's lives across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that address the Quadruple Aim: improved patient experience, better health outcomes, improved staff experience, and lower cost of care. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.

RF Medical Co., Ltd.

#503, 506, 254, Beotkkot-ro
Geumcheon-gu
Seoul
Korea
Email: overseas@rfa.co.kr
Phone: +82 221 084 200
Fax: +82 221 137 999
www.rfa.co.kr

**5**

As a manufacturer, RF Medical is dedicated to popularizing radiofrequency ablation treatments since 2003. Our extensive product range spans from tumor ablation such as liver and thyroid nodule ablation to even varicose vein treatments. Our sophisticated technology has allowed us to spread our business to more than 50 countries and our proven quality has granted us a strong reputation on the market.

As always, RF Medical strives with all its capabilities to create a healthier world by continuous investment in research and development. Products: Radiofrequency Generators, Radiofrequency Electrodes, Radiofrequency Catheters, Biopsy Needles, Infiltration Pump; Business area: Liver RFA, Bloodless Liver Resection, Lung RFA, Renal Cancer RFA, Varicose Vein Treatment, Disposable Biopsy Needle, Guiding system for lung biopsy needle & RFA, Thyroid RFA, Myolysis RFA, RFA for Bone Tumors, Endometrial Ablation, Treatment for various kinds of tumors, RF Snoring Treatment.

Siemens Healthcare GmbH

Henkestrasse 127
91052 Erlangen
Germany
Phone: +49 913 184 0
Fax: +49 913 184 292 4
Email: contact.healthcare@siemens.com
www.siemens-healthineers.com

**12**

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming

care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. Further information is available at www.siemens-healthineers.com.

Society of Interventional Oncology**18a**

2025 M St NW, Suite 800

DC 20036 Washington

United States

Contact: Dana Pinchoff

Email: dpinchoff@sio-central.org

Phone: +1 202 367 2338

On site: Cameron Curtis

Email: ccurtis@sio-central.org

Phone: +1 703 338 2919

www.sio-central.org

Established by WCIO, the Society of Interventional Oncology (SIO) serves as the only membership-based organization dedicated to the emerging field of Interventional Oncology. SIO works to further promote the mission to advance Interventional Oncology (IO) as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. Members receive discounted registration to SIO's Annual Scientific Meeting and opportunities to apply for exclusive research grants and earn free CME online at IO University. Become a member today and join us at SIO 2019 taking place in Boston, MA from June 8-11, 2019. Visit www.sio-central.org for the latest news and society updates.

Go with Resin. Make a difference



1. Single session treatment **Flexibility**
2. Natural flow-directed **Distribution**¹
3. The only SIRT with multiple RCT **Evidence**²⁻¹¹

References:

1. Burrill et al. *J Nucl Med Radiat Ther* 2011; **2**: 1.
2. Gray B et al. *Ann Oncol* 2001; **12**: 1711–1720.
3. Van Hazel G et al. *J Surg Oncol* 2004; **88**: 78–85.
4. Hendlisz A et al. *J Clin Oncol* 2010; **28**: 3687–3694.
5. van Hazel GA et al. *J Clin Oncol* 2016; **34**: 1723–1731.
6. Wasan HS et al. *Lancet Oncol* 2017; **18**: 1159–1171.
7. Pitton MB et al. *Cardiovasc Intervent Radiol* 2015; **38**: 352–360.
8. Kolligs FT et al. *Liver Int* 2015; **35**: 1715–1721.
9. Vilgrain V et al. *Lancet Oncol* 2017; **18**: 1624–1636.
10. Chow PKH et al. *J Clin Oncol* 2018; **36**: 1913–1921.
11. Rieke J et al. *J Hepatol* 2018; **68**: S365–S604, Abs. LBO-005.

SIRTeX

Sirtex Medical Europe GmbH
Joseph-Schumpeter-Allee 33
53227 Bonn
Germany

www.sirtex.com

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33

53227 Bonn

Germany

Email: info-emea@sirtex.comwww.sirtex.com

DIAMOND

SIRTeX**21**

Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients. Our innovative technology, SIR-Spheres® Y-90 resin microspheres (microscopic Yttrium-90 resin beads), is a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy (SIRT) to the liver. For inoperable liver cancer, it delivers high doses of radiation directly to the site of tumours whilst preserving normal liver parenchyma. SIR-Spheres Y-90 resin microspheres were approved in 2002 for use in the treatment of unresectable liver tumours within the European Union under a CE Mark.

They are presently used at 300+ institutions in Europe and the Middle East to treat a variety of unresectable liver metastases as well as hepatocellular carcinoma.

SIR-Spheres Y-90 resin microspheres are the most widely studied SIRT technology. Sirtex invested in a robust clinical trial programme of randomised clinical trials involving more than a hundred leading, international medical institutions, a thousand researchers and, more than 2,000 patients.

To date, more than 90,000 treatments have been delivered worldwide. SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Soteria Medical**33**

Meander 251

6825 MC Arnhem

The Netherlands

Email: Martijn.hoogenboom@soteria-medical.com

Phone: +31 263 763 426

www.soteria-medical.com

Soteria Medical BV & Biolitec biomedical technology GmbH. Soteria, a company located in Arnhem, The Netherlands, has developed a new approach to performing MRI guided prostate interventions by utilizing a fully MR-compatible robotic device for real time positioning in the MR scanner. Soteria's scope is the development, production and sales of medical devices and instruments – specifically in the field of MRI guided interventions. The initial product is the RCM (Remote Controlled Manipulator) for MRI guided prostate interventions. The RCM provides the ability to perform MRI guided biopsies within 30 minutes. Utilizing the patented pneumatic motors, the system allows for a large target range as well as the high accuracy to target for the smallest lesions visible on MR images. The RCM can also be used to support focal therapies such as Focal Laser Ablations (FLA). Biolitec is a German laser & fibre company presenting the biolitec Leonardo diode Dual laser and the specially designed LITT 2&3B FLA fibres for FLA of prostate tumor. The combination of the RCM positioning and Leonardo laser system provides a new possibility to accurately position a needle guide and homogeneously ablate the prostate tumor within the MRI.

STARmed

9

#B-14th floor, Daebang Triplaon
158, Haneulmaeul-ro, Ilsandong-gu
Goyang-si, Gyeonggi-do
10355
Korea
www.starmed4u.com/
www.facebook.com/starmed4u/

STARmed Co., Ltd. is a young and fast-growing company from South Korea, specializing in Radiofrequency technology. Passionately working on the best possible RF treatment, STARmed has collaborated with a number of Key Opinion Leaders in developing the most innovative Electrodes and leading-edge RF Technology specific to certain tumour types and clinical applications, in thyroid, liver, lung, kidney, myoma, bone, etc. STARmed is now recognized as global leader in Thyroid RFA. VIVA Multi RF System is uniquely different and powerful compared with past RF systems. It effectively generates two electrodes at the same time. It is safer and cost less than microwave result. Viva Multi RF System is idea for large and multiple lesions ablation. It has choice of six different modes. Octopus RF Electrode has unique and innovative design with 3 needles that can either be used as cluster of 0.5 cm distance from each. It is ideal for patients with large or multiple tumours and gets best result faster and bigger ablation. VIVA RF Electrode has unique and innovative design with adjustable active tip of 0.5 to 4 cm. Star RF Electrode-Fixed has wide range of length and gauge which makes it very appropriate for thyroid tumor ablation.

Surgnova Healthcare Technologies**8**

A: 5F. Yashi Blvd, No.22

Hongjunying Road, Chaoyang District

100012 Beijing

China

Mobile: +86 131 217 397 52

Phone: +86 106 411 826 5

Fax: +86 106 411 326 1

Email: mkt@surgnova.comwww.surgnova.com

To strive for creating high quality and cost effective surgical devices to make people live longer, healthier and better lives around the world, we set up Surgnova in 2015. Specialized in research and development of minimally invasive surgical devices, Surgnova leverages advanced technology and deep clinical knowhow to design and deliver excellent surgical products for customers. We started with devices for minimally invasive surgical procedures for tumor treatment, including interventional oncology and tumor resection. To fulfill the rapidly-expanding needs, we have been enhancing our three product lines of interventional oncology devices, minimally invasive surgical devices and surgical robots. In addition, we're entering cardiovascular intervention and orthopedic surgical fields in the near future. We are dedicated to creating top-level products with continuous innovation and technology breakthrough. We only deliver the highest quality products meeting the needs of our customers around the globe. We are committed to providing the access to minimally invasive, safe and efficient surgical operations for people worldwide.

Terumo Interventional Systems

Interleuvenlaan 40

3001 Leuven

Belgium

Phone: +32 163 812 11

www.terumo-europe.com

DIAMOND

**13**

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with over \$5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo develops products for interventional radiologists that specialize in treating patients with oncological indications. Rising to the challenge of creating innovative treatments for patients, we bring you a complete range of interventional oncology products that focus on: Access, Loco-regional treatments ranging from ablation, TACE and SIRT, Endovascular embolization. As a pioneer in interventional oncology, Terumo is committed to bringing you cutting-edge technology to support your loco regional patient needs. We are committed to supporting our comprehensive product portfolio by a well-trained field force and solid clinical evidence.

Varian Medical Systems International AG**30**

Hinterbergstrasse 14


6312 Steinhausen

Switzerland

Contact: Tim Clark

Email: Tim.Clark@varian.comwww.varian.com

Varian focuses energy on saving lives by equipping the world with advanced technology for fighting cancer. The company is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian employs approximately 7,000 people at sites around the world. For more information, visit www.varian.com and follow @VarianMedSys on Twitter.



Imprint

CIRSE Central Office

Neutorgasse 9
1010 Vienna, Austria

Phone: +43 1 904 2003

Fax: +43 1 904 2003 30

Email: info@cirse.org

www.ecio.org

The ECIO 2019 Pocket Guide

In case of any queries or comments,
please contact us at **info@cirse.org**

© Cardiovascular and Interventional Radiological Society
of Europe / 2019

GraphX by L O O P . E N T E R P R I S E S media
www.loop-enterprises.com




PUSHING BOUNDARIES

We strive for perfection in our craft,
so that you can perfect yours.

TREAT LIVER CANCER WITH TERUMO

You have the know-how, we have
high quality tools, let's master liver
cancer complexity together.



PUSHING BOUNDARIES



TERUMO
INTERVENTIONAL
SYSTEMS

www.terumo-europe.com

Terumo is the authorized distributor of LifePearl microspheres, TATO, MedSphere, QuiremSpheres and QuiremScout. Not all products are available for sale in all countries. This information is provided only in respect to markets where these products are approved or cleared. Not all products are cleared or approved in the U.S.A. by the Food and Drug Administration. Please contact your Terumo local sales representative for more information.

TERUMO
INTERVENTIONAL
SYSTEMS

www.terumo-europe.com

